



Febrer 2013

## DADES PERSONALS - CV

---

Nom i cognoms: Pere Gascón i Vilaplana  
Professió: Metge i Doctor en Medicina i Cirurgia  
Data de naixement: 29 de maig de 1949  
Lloc: Barcelona  
Col·legi de Metges de Catalunya i Balears no.: 8.560  
Hospital:  
Servei d'Oncologia Mèdica Hospital Clínic  
C/ Villarroel, 170  
08036 BARCELONA  
Telèfon: 93-227.54.02  
Fax: 93.454.65.20  
Adreça Electrònica: gascon@clinic.ub.es

## 1. FORMACIÓ UNIVERSITÀRIA

---

### a. Pregraduada

1963-1968 Pèrit Industrial. Escola d'Enginyers Tècnics Industrial de Barcelona.

### b. Graduada

1968-1974 Llicenciat en Medicina i Cirurgia. Universitat de Barcelona. Facultat de Medicina.

1970-1975 Llicenciat en Filosofia i Lletres, branca de Historia de la Filosofia. Universitat de Barcelona. Facultat de Filosofia i Lletres

1974-1975 Professor No Numerari. Universitat de Barcelona. Facultat de Medicina.

1974-1977 Doctor en Medicina i Cirurgia (1977). Universitat de Barcelona. Facultat de Medicina.

1975-1977 Research Scientist. New York University Medical Center, Departament de Farmacologia, New York, EUA.

## **2. FORMACIÓ POST-DOCTORAL**

---

1973-1974 Alumne Intern per Oposició, Càtedra de Farmacologia, Facultat de Medicina, Barcelona

1974-1975 Professor No Numerari (PNN) Cátedra de Farmacologia, Facultat de Medicina, Barcelona

1975-1977 Assistant Research Scientist, Dept. of Pharmacology, New York University Medical Center.

1977-1978 Intern, Internal Medicine, Coney Island Hospital-Downstate Medical Center, State University of New York.

1978-1979 Junior Resident, Internal Medicine, Coney Island Hospital, New York.

1979-1980 Senior Resident, Internal Medicine, Coney Island Hospital, New York.

1980-1984 Medical Staff Fellow, Clinical Hematology Branch, NHLBI, National Institutes of Health (NIH), Bethesda, Maryland. Supervisor: Dr. Neal Young and Dr. Arthur Nienhuis. Plaça obtinguda mitjançant concurs de merits i entrevistes. Tots els candidats eren nordamericans

1984-1985 Clinical Fellow, Division Hematology-Oncology, Barnes Hospital, Washington University, St. Louis, MO. Supervisor: Dr. Stuart Kornfeld and Dr. Phillip Majerus (ambdós membres de la National Academy of Sciences).

## **3. LLICÈNCIES**

---

1974 Acadèmia Ciències Mèdiques de Catalunya i Balears. Núm. Col.legiat 8560

1975 Estat de New York. Llicència núm. # 139932. Inactiva.

1985 Estat de New Jersey. Llicència núm. # 46690. Caduca 31/12/2012

## **4. CERTIFICATS**

---

a. Diploma , American Board of Internal Medicine.

b. Diploma, American Board of Internal Medicine - Hematology.

c. Diploma, American Board of Internal Medicine - Oncology.

## **5. CERTIFICAT DE NARCÒTICS**

---

- a. NJ CDS D42447. Data Caducitat: 31/12/2012
- b. NJ DEA BG0671758. Data Caducitat: 31/12/2012

## **6. CÀRRECS A LA UNIVERSITAT**

---

- 1974-1975 Professor No Numerari. Universitat de Barcelona. Facultat de Medicina.
- 1984-1985 Assistant, Medicine. Washington University School of Medicine, St. Louis, Missouri.
- 1985-1991 Assistant Professor in Medicine, Department of Medicine, UMDNJ-New Jersey Medical School, Newark.
- 1990-1999 Adjunt Member. Graduate Faculty, Department of Biology, Rutgers University, Newark, N.J.
- 1991-1997 Associate Professor in Medicine (amb *tenure/càrrec vitalici*), Department of Medicine, UMDNJ - New Jersey Medical School, Newark, New Jersey.
- 1997-1999 Professor in Medicine, Department of Medicine, UMDNJ - New Jersey Medical School, Newark, New Jersey.
- 2001-2008 Professor Associat, Facultat Medicina. Universitat de Barcelona.
- 2003- Coordinador Assignatura Oncologia Clínica
- 2009- Professor Titular, Facultat Medicina. Universitat de Barcelona
- 2011- Habilitació per a Catedràtic d'Universitat

## **7. CÀRRECS A L'HOSPITAL**

---

- 1985-1999 Cap de Servei de la Divisió d'Hematologia, Department of Medicine, UMD-New Jersey Medical School, Newark, N.J.
- 1985-1989 Co-director del Programa de Formació d'Hematòlegs i Oncòlegs (Fellowship Program).
- 1986-1999 Chairman del Comitè de Transfusions.
- 1989-1990 Director en funcions de la Divisió d'Oncologia Mèdica. Department of Medicine, UMD-NJ Medical School.
- 1989-1994 Director del Programa de Formació d'Hematòlegs i Oncòlegs, UMDNJ-New Jersey Medical School.
- 1989-1994 Director de la Unitat de Quimioteràpia.
- 1990-1994 Cap de Servei de la Divisió d'Hematologia/Oncologia, UMDNJ, NJ Medical School.

- 1994-1995 Cap de Servei d'Hematologia i Hemoteràpia de l'Hospital de Cruces de la Seguretat Social, Barakaldo, Biscaia.
- 1995-1999 Cap de Servei de la Divisió d'Hematologia, UMDNJ, New Jersey Medical School.
- 1999 - Cap de Servei d'Oncologia Mèdica. Hospital Clínic. Barcelona.
- 1999- Coordinador de Recerca de l'Institut Clínic de Malalties Hemato-Oncològiques (ICMHO). Hospital Clínic.

#### **8. ALTRES CÀRRECS PROFESSIONALS**

---

- 1989-1990 Investigador Principal (PI), UMD-NJMS Eastern Cooperative Oncology Group (ECOG).
- 1990-1994 Investigador Principal (PI) en el tractament de linfomes mitjançant l'ús d'anticossos monoclonals, Center for Molecular Medicine and Immunology (CMMI), Newark.
- 1996-1999 Director i Fundador, University Hospital-Sickle Cell Center.
- 2004-2006 President de la Secció d'Oncologia de l'Acadèmia de Ciències Mèdiques de Catalunya i Balears.

#### **9. MÈRITS I HONORS**

---

- 1968-1970 Beques del Govern Espanyol, Universitat de Barcelona.
- 1973 Alumne Intern per Oposició, Càtedra de Farmacologia, Universitat de Barcelona, Facultat de Medicina.
- 1986 Fellow American College of Physicians (FACP).
- 1986 Sigma Xi - Scientific Research Society.
- 1987 UMDNJ - New Jersey Medical School, Premi Extraordinari al Mèrit Professional.
- 1988 Appreciation Certificate Leukemia Society of America
- 1988 Appreciation Certificate New Jersey Organ and Tissue Sharing
- 1992 Fellow, New York Academy of Medicine
- 1994 UMDNJ-New Jersey Medical School, Premi de la Junta Facultativa a l'excel.lència acadèmica.
- 1995 American College of Physicians, NJ Chapter, 1995 Laureate Award (escollit millor metge de l'any de l'Estat de New Jersey)
- 1997 Alpha-Omega-Alpha National Honor Society, NJMS Chapter

1998 "Best Doctors in America"

## 10. PARTICIPACIÓ A COMITÈS

### a) NACIONAL I REGIONAL :

- 1985-1990 Membre, Eastern Cooperative Oncology Group (ECOG)
- 1985- National Cancer Institute (NCI) Investigador núm. #14527
- 1987-1989 Membre, Comitè Executiu, NJ Professional Education Network for Organ Donation (NJPEND), The Transplant Foundation of New Jersey
- 1988-1998 Membre, Comitè Executiu, North Jersey AIDS Alliance
- 1989-1993 Membre, New Jersey State Sub-committee on Bone Marrow Transplantation Guidelines
- 1989-1990 Investigador Principal (PI), UMD-New Jersey Medical School, Eastern Cooperative Oncology Group (ECOG)
- 1990-1992 Membre, Board of Governors, UMD-New Jersey Medical School/DS Chapter, American Association of University Professors (AAUP)
- 1991-1994 Membre, The Center for Molecular Medicine and Immunology CMMI) Institutional Review Board (IRB)
- 1991-1999 Membre Advisor, Ruth Estrin Goldberg Memorial for Cancer Research
- 1991-1996 Membre, Transfusion Medicine Academic Award-NIH-Representing Nwk.
- 1991-1999 Membre, New Jersey State Sickle Cell Anemia Advisory Group Adult Hematology)
- 1993-1997 Membre, Core Clinical Advisory Group to the New Jersey Commissioner of Health on Transplantation
- 1995-1996 Contributor, Certification and re-Certification, Internal Medicine Board, Hematology Subspecialty
- 1997-1999 Ad Hoc Membre, NIH, NHLBI Hematology II Study Section
- 2000- Membre, Scientific Committee-Asociación Española Contra el Cancer (AECC), Spanish Cancer Society
- 2001- Membre, Scientific Committee, SOLTI oncology treatment group
- 2003- Patró, Fundación Medicina y Humanidades (Barcelona)
- 2006 Membre, Monitoring Committee Centre de Medicina Regenerativa de Barcelona (Dr. Juan Carlos Izpisúa)

2005	Membre, Development of the National Guidelines on the use of anti-emetic Agents
2007	Membre, Development of the National Guidelines on the use of erythropoietic stimulating Agents
2007	Membre, Scientific Committee Fundación CELLEX, Barcelona (Spain)
2007	President Fundació "On Vida", Spanish oncologists (unrestricted educational grant by Roche)
2008	Membre Comitè Científic Fundación FIDES, Madrid (Spain)
2008	Co-Director "Foro Healthcare", Fundación para la Investigación sobre el Derecho y la Empresa (FIDES)
2009-	Patró, Fundació Privada Patronat de l'Hospital Oncològic de Catalunya - Fundació Catalunya contra el Càncer (FOC)
2009	Membre Fundador y Tresorer de la Fundació ECO (Fundación para la Excelencia y la Calidad Oncológica)
2009-2012	Vocal de la Junta de l'Associació Espanyola per la Recerca Oncològica (ASEICA)

b) FACULTAT DE MEDICINA :

1986-1989	Membre, UMD-New Jersey Medical School Institutional Review Board (IRB)
1988-1994	Membre, UMD-New Jersey Medical School - Biomedical Research Support Grant Committee
1988-1994	Membre, Foundation UMD-New Jersey Medical School, Grants Committee
1988	Membre Comitè , Ph.D Dissertation Mrs. Alicia Alonso, Department of Pathology
1989	Consultant - NIH Grant "The Psychoimmunology of Adolescents at Risks for AIDS" P.I. Steven E. Keller, Ph. D.
1990	Membre Comitè, Master Thesis Dissertation Mr. Paul Chang, Department of Pathology
1990-1993	Director Tesi Doctoral Ms. Pranela Rameshwar, Department of Biology, Rutgers University
1990-1994	Advisory Committee Member, Ph.D Thesis Ms. Lisa Pettera, Department of Pathology
1991	Membre Comitè, Masters Thesis Dissertation Mrs. Linda K. Ellis, Department of Pathology
1991	Membre, Search Committee for Chairperson Department Pharmacology and Toxicology
1993	Membre Comitè, Ph.D Dissertation Ms. Sarah S. Kolla, Department of Pathology

1995	Membre, Faculty Committee on Appointments and Promotions (FCAP)
1996	Membre, Faculty Committee on Institutional Planning and Development
1997	Membre Comitè, Ph.D Dissertation Mr. Felix N. Agbo, Department of Pharmacology and Toxicology
1997	Membre Comitè, Master Thesis Dissertation Mr. Daniel Brennan, Department of Pathology
2000	Membre Comitè, Ph.D Dissertation Mrs. Susana Puig, Department of Dermatology, Barcelona University
2001	Membre Comitè, Ph D Dissertation, Mr. Francesc Mitjans, Department of Biology, Barcelona University
2002	Membre Comitè, PhD Dissertation, Ms. Salvadoria Delgado Rivilla, Department of Medicine, Barcelona University
2003	Membre Comitè, PhD Dissertation, Mr. Xavier Bessa i Casserras, Department of Medicine, Barcelona University
2003-	Co-director Masters Course in Breast Cancer (Senology)
2005	Membre Comitè, PhD Dissertation, Ms. Núria Laso, Department of Pharmacology, Barcelona University
2005	Membre Comitè, PhD Dissertation, Ms. Eva Martínez Balibrea, Department of Medicine, Universitat Autònoma de Barcelona (UAB). Title: Polimorfismes genètics i quimioteràpia en el càncer de còlon i recte metastàtic. Anàlisi dels gens TS, UGT1A1 i XRCC1.
2006	Membre Comitè, PhD Dissertation, Mr Josep M <sup>a</sup> Domingo Domènech, Department of Medicine, Barcelona University. Title: Implication of nuclear factor-kB (NF-kB) transcription factor in prostate cancer progression and chemoresistance
2007	Membre Comitè, PhD Dissertation, Ms Elisabet Ametller Pastallé, Department Biology. Title: "Acció anticaquèctica del formoterol i efectes sobre la regeneració muscular".
2007	Membre Comitè, PhD Dissertation, Ms Cristina Nadal Sanmartín, Department Medicina, Universitat de Barcelona. Title: Mecanismos de metástasis en cáncer colorrectal: Identificación y papel de las <i>stem cell</i> tumorogénicas.
2007	Membre Comitè, PhD Dissertation, Ms Sandra Perez Torras, Department Biochemistry, Universitat de Barcelona. Title: Modulación de la sensibilidad a la gemcitabina mediante estrategias de terapia génica en cáncer de páncreas humano.
2007	Membre Comitè, PhD Dissertation, Mr José Muñoz Langa, Department Medicina, Universitat de València. Title: Optimización del tratamiento de la anemia inducida por quimioterapia con eritropoyetina recombinante humana en el paciente con cáncer: desarrollo de modelos predictivos de anemia y de respuesta a la eritropoyetina.

2007	Director Tesi Doctoral to Ms Noemí Reguart, Department Medicina, Universitat Barcelona. Title: “Análisis del gen <i>Wnt inhibitory factor</i> (WIF) como proteína reguladora de la vía del <i>Wingless-int</i> (Wnt) en cáncer”
2009	Membre Comitè, PhD Dissertation, Ms Ana María Santaballa Bertrán, Department of Medicine-Oncology, Facultad de Medicina y Odontología de Valencia, Universitat de València, Title: Diferencias entre los cánceres de mama diagnosticados clínicamente y los detectados en un programa de cribado.
2009	Membre Comitè, PhD Dissertation, Ms Anna Vidal, Department Biochemistry, Universitat de Barcelona. Title: Inhibició dels receptors de IGF-I i EGF en models de càncer de pàncrees humà.
2009	President Comitè, PhD Dissertation, Ms Clara Montagut, Department Medicine, Universitat de Barcelona. Title: Biomarcadores de respuesta y mecanismos de resistencia a terapias inhibidoras de cinasa en cáncer: papel de RAF.
2009	President Comitè, PhD Dissertation, Ms Mª del Mar Mañu Pereira, Department Ciències Fisiològiques, Universitat de Barcelona. Title: Aportación al estudio de las anemias hereditarias en Cataluña. Impacto de la inmigración.
2009	Membre Comitè, PhD Dissertation, Mr Xavier Frigola Baró, Departament Fisiologia, Universitat Barcelona. Title: “Mecanismes cel.lulars i moleculars en la tolerància immunitària vers el càncer renal”.
2010	Membre Comitè, PhD Dissertation, Mr Antonino Agrusa, Facolta' di Medicina e Chirurgia. Università degli Studi di Palermo. Title: “Gastrointestinal stromal tumors (GISTs): focus on histopathological diagnosis and biomolecular features”. Tutor: Prof. G. Gulotta
2010	Membre Comitè, PhD Dissertation, Mr Salvatore D'Arpa, Facolta' di Medicina e Chirurgia. Università degli Studi di Palermo. Title: “The retroauricular skin: a hidden tissue bank in post-oncological ear reconstruction”. Tutor: Prof. A. Cordova
2010	Membre Comitè, PhD Dissertation, Mr Francesco Paolo Fiorentino, Facolta' di Medicina e Chirurgia. Università degli Studi di Palermo. Title: “Down-regulated expression of RBL2 tumor suppressor in lung cancer cells is associated with loss of CTCF binding, loss of nucleosome assembly and altered histone transcriptional modifications”. Tutor: Prof. A. Russo
2010	Membre Comitè, PhD Dissertation, Mrs Chiara Intrivici , Facolta' di Medicina e Chirurgia. Università degli Studi di Palermo. Title: “Strategies for cancer vaccine development”. Tutor: Prof. N. Gebbia
2010	Membre Comitè, PhD Dissertation, Mrs Alessandra Malato, Facolta' di Medicina e Chirurgia. Università degli Studi di Palermo. Title: “Use of protein C concentrate in adult patients with Cancer and disseminated intravascular coagulation”. Tutor: S. Siragusa
2010	Membre Comitè, PhD Dissertation, Mr Christian Diego Rolfo, Facolta' di Medicina e Chirurgia. Università degli Studi di Palermo. Title: “ Relationship between metabolic activity (SUVmax) by 18-FDG PET and histology, stage, survival and Epidermal Growth Factor Receptor (EGFR) mutations in patients with non-small cell lung cancer (NSCLC)”. Tutor: Prof. A. Russo

2010	Membre Comitè, PhD Dissertation, Ms Marina Roustan. Facultat de Psicologia, Universitat de Barcelona. Títol: 'Estudio observacional de ayuda interactiva en el postratamiento de cáncer de mama: reuniones GAFA'.
2010	Membre Comitè, PhD Dissertation. Mr Antonio Galan Brotons. Departament Medicina, Universitat de València. Títol: 'Estudio epidemiológico de los tumores de pulmón, colon y recto, en el Departamento de salud 04 (Hospital de Sagunto) de la Comunidad Valenciana.'
2011	Membre Comitè, PhD Dissertation. Mr Antonio Galan Brotons. Departament Medicina, Universitat de València. Títol: 'Estudio epidemiológico de los tumores de pulmón, colon y recto, en el Departamento de salud 04 (Hospital de Sagunto) de la Comunidad Valenciana.'
2011	Avaluador Extern, PhD Dissertation. Mrs Carmen Martínez Valero. Departament Psicologia, Universidad de Granada. Títol: 'Psico-Oncología e Indefensión Aprendida: Un estudio clínico'.
2011	Committee President, PhD Dissertation, Mr José María García Bueno. Hospital de Albacte. Title: 'Heterogeneidad tumoral y cinética celular, cultivo de células neoplásicas'.
2011	Committee Member, PhD Dissertation, Ms Swapna Venkata Vaddi. University of Manchester. Title: The role of the nervous system in the immune response to trichinella spiralis infection.
2011	Committee Member, PhD Dissertation, Ms Rosa Puigpinós i Riera. Department Salut Pública i Legislació Sanitària, Universitat Barcelona. Title: 'Desigualtats en càncer en àrees urbanes: mortalitat i cribatge'.
2011	Committee Member, PhD Dissertation, Ms Joana Marquez Clavijo, Universidad País Vasco. Title: 'Utilización de la perturbación génica homocigota al azar para identificar genes implicados en la retención microvascular y adhesión endotelial hepática del cáncer de colon humano HT-29'.
2012	Co-Director Tesi Doctoral, Ms Susana Garcia Recio, Universitat de Barcelona. Títol: Citoquinas proinflamatorias de la familia de las taququininas son responsables de la modulación del fenotipo y patrón molecular de células de cáncer de mama.
2012	Co-Director Tesi Doctoral, Ms Carme Font i Puig, Universitat de Barcelona. Títol: Malaltia tromboembòlica venosa en el pacient oncològic.
c) HOSPITAL :	
1983-1984	Member, NIH Transfusion Committee (NLHBI representative), Bethesda, Maryland
1985-1988	Member, UMD-New Jersey Medical School, Cancer Education Committee
1985-1986	Member, UMD-New Jersey Medical School, Transfusion Committee
1986-1999	Chairman, UMD-New Jersey Medical School, Transfusion Committee
1986-1999	Member, UMD-New Jersey Medical School, Radiation Safety Committee

1986-1999	Member, UMD-New Jersey Medical School, Radiation Human Usage Committee.
1987-1999	Non-Member, UMD-New Jersey Medical School, Executive Committee
1987-1995	Member, UMD-New Jersey Medical School, Oncology Committee
1987-1989	Member, UMD-New Jersey Medical School, Blood Procurement Liver Transplantation Task Force
1988-1989	Member, Outpatient Transfusion Committee
1990-1994	Principal Investigator, Lymphoma Protocols, Center for Molecular Medicine and Immunology (CMMI)
1999-	Member, Executive Committee, Institut Clinic Malalties Hemato-Oncològiques, ICMHO.
2000-	Member, Institut per la Recerca Biomèdica Agustí Pi i Sunyer (IDIBAPS)
2003-	Member, Director's Advisory Committee in Cancer, Clinic Univ. Hospital-Barcelona Medical School
2005-	Member, Institutional Review Board (IRB)-Ethics Committee, Hospital Clínic
2006-	Chairman, Director's Advisory Committee in Cancer, Clinic Univ. Hospital-Barcelona Medical School
2005-	Member, Hospital Scientific Committee
2007-	Chairman, Director's Advisory Committee in Cancer, Clinic Univ. Hospital-Barcelona Medical School

d) DEPARTAMENT :

1985-1989	Member, UMD-New Jersey Medical School, Department of Medicine Quality Assurance Committee
1986-1992	Member, UMD-New Jersey Medical School, Department of Medicine. Institutional Review Board (IRB)
1990	Member, UMD-New Jersey Medical School, Department of Medicine for the evaluation and improvement of student's performance
1999	Research Coordinator, Department of Hematology-Oncology, Clinic University Hospital, Barcelona, Spain

e) INTERNACIONAL :

1987-1998	Membre, Advisory Committee to the Government of Spain (Office of the Presidency) For Science, Health and Research Policy
-----------	--

1990	Revisor - Agencia Nacional de Evaluación (Spanish Agency for Grants evaluation)
1999-2005	Membre, E.C.A.S.( European Cancer Anemia Survey)
2001-2005	Revisor External Panel, Oncology Research Grants, Ministry of Science of Portugal. Fundação para a Ciência e a Tecnologia
2002	Revisor, Abstracts, International Society Experimental Hematology (ISEH)
2003	Revisor, Abstracts, International Society Experimental Hematology (ISEH)
2004	Revisor, Abstracts, International Society Experimental Hematology (ISEH)
2002	Revisor External Panel, Portuguese Oncology Departments (Lisbon, Coimbra and Oporto), Ministry of Science of Portugal. Fundação para a Ciência e a Tecnologia
2005	Membre "ad hoc" for the European Agency for the Evaluation of Medicinal Products (EMEA)
2005-2012	Chairman and Scientific Director of the 1 <sup>st</sup> , 2 <sup>nd</sup> , 3 <sup>rd</sup> , 4 <sup>th</sup> , 5 <sup>th</sup> , 6 <sup>th</sup> 7 <sup>th</sup> 8 <sup>th</sup> 9 <sup>th</sup> International Symposium in Translational Oncology, Barcelona
2006-	Membre, Independent Data Monitoring Committee (IDMC) on Epoetins Safety <a href="#">(protocol endorsed by the FDA)</a>
2008-	Co-director del Curs Annual de la European School of Oncology - EORTC-Anemia Working Party. Anemia, Neutropenia, thromocytopenia and Cancer Course: 2008, 2009, 2010, 2011, 2012
2009-	<a href="#">Chairman, Steering Committee protocol 20070782 on safety of darbepoetin alfa in lung cancer (protocol endorsed by the FDA)</a>
2012	IMembre, Scientific Committee of the 39 <sup>th</sup> European Society of Medical Oncology (ESMO)-Subcommitté on "Supportive and Palliative care"

f) EDITORIAL BOARDS :

1978-1995	Membre, Clinical Pharmacology Section, Jano Spain
1982-1983	Membre, M.I.R. Medicina del Postgrado, Spain
1984-1999	Membre, Neoplasia, Spain
1995-	Membre, Oncology Section, Jano, Spain
2001-	Membre, Research Communications in Molecular Pathology and Pharmacology
2003-	Membre, Revista de Oncología
2005-	Membre, Oncología, Spain

2005-	Membre, Cancer & Chemotherapy Reviews
2006-	Editor, Translational Oncology Reviews
2007	Co-Editor. ASCO: Breast Cancer. Current Clinical Issues & Future Trends. Adjuvant and neoadjuvant treatment
2008	Co-Editor. ASCO: Translational Oncology. Current clinical issues & future trends. Oncology, Self-Study Series
2009	Co-Editor. ASCO: Renal Cancer. Current clinical issues & future trends. Oncology, Self-Study Series
2009	<u>Co-Editor. ASCO: Colo-Rectal Cancer. Current clinical issues &amp; future trends. Oncology, Self-Study Series</u>
2009	Co-Editor. ASCO: Angiogenesis. Current clinical issues & future trends. Oncology, Self-Study Series
2009	Editor-in-Chief, ASCO: Breast Cancer. Current clinical issues & future trends. Oncology, Self-Study Series.
2011	ESMO Clinical Collection. Volume 1: Focus on Lung Cancer: Biology. Molecular markers
2011	ESMO Clinical Collection. Volume II: Focus on Lung Cancer: Early and Locally advanced disease. Clinical Guidelines
2012	ESMO Clinical Collection. Volume III: Focus on Lung Cancer Metastatic stage. Treatment

g) REVISOR:

1986-Present	Reviewer, Blood (first reviewer)
1991-Present	Reviewer, Veterans Administration Merit Review Grants
1995-Present	Reviewer, Annals of Hematology (former - Blut)
1995-Present	Reviewer, Proceedings of the National Academy of Sciences (PNAS)
1996-Present	Reviewer, Experimental Cell Research
1997-Present	Reviewer, Journal of Immunology (first reviewer)
1998-present	Reviewer, The Wellcome Trust (U.K.)
2000-present	Reviewer, Life Sciences
2000-present	Reviewer, Revista de Oncología
2000-present	Reviewer, Medicina Clínica
2002-present	Reviewer, Leukemia
2003-present	Reviewer, The Hematology Journal
2002-2004	Reviewer, abstracts in International Society Experimental Hematology (ISEH)
2004-present	Reviewer, International Journal of Cancer
2004-present	Reviewer, Cytokine
2005-present	Reviewer, Anticancer Therapy
2005-present	Reviewer, Clinical & Experimental Metastasis
2005-present	Reviewer, European Respiratory Journal
2005-present	Reviewer, Journal of Neuroimmunology
2005-present	Reviewer, Oncología
2005-present	Reviewer, Expert Review of Anticancer Therapy

2005-present	Reviewer, International Journal of Biochemistry and Cell Biology
2006-present	Reviewer, Cancer Letters
2006-present	Reviewer, Cancer, Chemotherapy and Pharmacology
2007-present	Reviewer, Leukemia Research
2007-present	Reviewer, The Oncologist
2007-present	Reviewer, Cancer Investigation
2007-present	Reviewer, Breast Cancer Research
2007-present	Reviewer, Brain, Behavior, and Immunity
2007-present	Reviewer, The Journal of Biological Procedures
2007-present	Reviewer, Annals of Oncology
2008-present	Reviewer, Journal of Cellular and Molecular Medicine
2008-present	Reviewer, Biological Procedures on Line
2008-present	Reviewer, Current Stem Cell Research & Therapy (CSCR)
2008-present	Reviewer, International Journal of Hematology
2008-present	Reviewer, The Lancet
2008-present	Reviewer, Oncology
2009-present	Reviewer, British Journal Haematology
2009-present	Reviewer, Nephrology Reviews
2009-present	Reviewer, Endocrine-Related Cancer
2009-present	Reviewer, Current Pharmacogenomics and Personalized Medicine
2010- present	Reviewer, Expert Opinion on Biological Therapy
2010-present	Reviewer, Oncology Reviews
2010-present	Reviewer, Advances in Hematology
2011-present	Reviewer, Future Oncology
2011- present	Reviewer, Expert Review of Hematology
2011-present	Reviewer, Plos One
2011- present	Reviewer, Proceedings of the National Academy of Sciences of the United States of America (PNAS)
2011- present	Reviewer, Clinical and Experimental Pharmacology and Physiology
2011- present	Reviewer, Expert Opinion On Therapeutic Targets
2012-present	Reviewer, Expert Review of Pharmacoeconomics & Outcomes Research
2012-present	Reviewer, Expert Opinion on Drug Safety
2012-Present	Reviewer, Leukemia & Lymphoma
2012-Present	Reviewer, Cancer Research-UK-Grants
2012-Present	Reviewer, Critical Reviews in Oncology/Hematology
2012-Present	Reviewer, European Science Foundation
2012-Present	Reviewer, Blood Transfusion
2013-Present	Reviewer, BMC Cancer

## 11.- CONFERÈNCIES SELECCIONADES

- American Society of Hematology (San Francisco, 1983)
- International Society of Hematology (Cancun, Mexico, 1984)
- American Society of Hematology (Washington, DC, 1987)
- American Society of Hematology (Atlanta, 1989)
- Spanish Society of Scientists in U.S.A (Pittsburgh, 1991)
- American Association of Immunologists/Clinical Immunology Society (Denver, 1993)
- International Symposium on Molecular Biology of Hematopoiesis (Genoa, Italy, 1995)
- Annual Meeting Biology Society United Kingdom (Canternbury, U.K.,1996)

- Fourth International Congress of the International Society for NeurolimmunoModulation (Lucarno, Switzerland, 1999)
- International Conference “Towards an understanding of the molecular basis of myeloproliferative disorders” (München, Germany 2000)
- First International Congress of the Myeloproliferative Diseases and Myelodysplastic Syndromes (New York, 2001)
- European Cancer Conference-ECCO (Lisbon, Portugal 2001)
- International Symposium “ The Substantial Impact of Anemia and Fatigue on Breast and Gynecologic Cancer Patients” (Munich, Germany, 2002)
- ICACT (Paris, France, 2003)
- Third International Symposium on Advances in Cancer Anemia Treatment (Vienna, Austria, 2003), 10<sup>th</sup> World Conference on Lung Cancer (Vancouver, Canada, 2003)
- ECCO 12-The European Cancer Conference “Optimizing Management of Patients with Solid Tumors-Efficacy evaluation of Anemia Treatments” (Copenhagen, Denmark, 2003)
- Belgian Society of Hematology Annual Meeting (Brussels, Belgium, 2004)
- Mexican Society of Hematology (Querétaro, Mexico, 2005)
- First International Symposium on Target Therapy-Mexican Society of Medical Oncology (Mexico City, D.F., 2005)
- Grand Rounds-Invited speaker McGill University, Montreal, Canada (25-26/1/2006)
- Fourth PhD course “Investigació aplicada i neoplàsies digestives”. “Las nuevas moléculas en el tratamiento del cáncer de colon y recto”, 11 march 2006
- Centro de Investigaciones de Cáncer de Salamanca “Papel de las Taquikininas en el desarrollo del Cáncer de mama”, Nov. 2006
- “Fármacos que bloquean la estimulación oncogénica” Centro Nacional Investigaciones Cáncer (CNIO) 2004, 2005, 2006, 2007, 2008, 2009
- European Organization for Research and Treatment of Cancer (EORTC): Anemia and cancer Therapy, Rome 30th May, 2007
- Universidad de Salamanca-Hospital Medical Grand Rounds: Angiogenesis Tumoral, May 3rd, 2007, Salamanca
- Annual Meeting Spanish Society of Cancer Research (ASEICA): “Tumoral Stem Cell”, Las Palmas de Gran Canaria, May 11th, 2007
- First World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers, Chairman session “Case Presentations”, Barcelona September 7th, 2007
- 14th European Cancer Conference (ECCO), Chairman session “Haematological growth factors: are they really worth their cost? Barcelona 27th September, 2007
- First Joint Meeting Symposium ASCO-SEOM in Oncology “Focus on Angiogenesis”, Madrid October 2nd, 2007.
- Guest speaker to the Venezuelan Society of Hematology “ Indications and Safety concerns on the use of erythropoietic agents, Caracas (Venezuela), August 2008
- Guest speaker Philippine Society of Medical Oncology “Current use of erythropoietic agents”, Manila (Philippines), September 2008
- Guest speaker Venezuelan Society of Medical Oncology “Current use of erythropoietic agents. Safety concerns”, Caracas (Venezuela October 2008
- Invited speaker Sociedad Mexicana de Anemia Aplásica “El sistema nervioso como regulador de la hematopoyesis”, Mexico D.F. November 7th, 2008
- Invited speaker, Research Grand Rounds “Moffitt Cancer Center-University of South Florida” on “ Role of Substance P (SP) on the activation of EGFR family members. Potential implications for breast cancer treatment”, Tampa, Florida (USA), April 2009
- Invited Guest “Role of maintenance chemotherapy in advanced breast cancer” Scientific Symposium ECCO-ESMO september 2009
- Invited speaker-educative session, Annual congress of the European Association of Nuclear Medicine “Monitoring therapy responses in Oncology” Barcelona october 2009

- [Invited speaker, XVIII Congresso Brasiliero de Cancerologia “Safety of erythropoietins and current clinical usage”, Curitiba, Brasil, 28-31 October, 2009](#)
- Co-director and speaker: 9th Course Anemia, Neutropenia, Thrombocytopenia and Cancer Course, EORTC, Vienna, Austria, 19-20th March, 2010
- Invited Speaker: “Tumor microenvironment as a new therapeutic target”, 3rd International Symposium in Personalized Medicine, Poznan, Poland, 22-24 April, 2010
- Facolta' di Medicina e Chirurgia. Università degli Studi di Palermo. Title: Cancer Stem Cell: Current controversies, April 2010
- II Jornada CNIO, Oncología Traslacional en cáncer de mama “Utilización de nuevas tecnologías para el tratamiento individualizado en cáncer de mama” Madrid, Mayo 2010
- Seminario CNIO. Título: “The role of tachykinins in breast cancer”. Madrid, Septiembre 2010
- Invited speaker-educative session, Sociedad Venezolana de Oncología. Título: “Manejo de la anemia en el paciente oncológico. Valencia (Venezuela), noviembre 2010
- Conferenciant convidat per la Societat Mexicana d’Oncologia. Títol: Seguretat de les eritropoietines. Receptors d’eritropoietines. Mèxic, Novembre 2010
- Reial Acadèmia Ciències Mèdiques. Títol: “El concepte de neurohematopoesi. Importància per la Fisiologia de la Sang i el procés metàstic”, 15/03/2011.
- Conferenciant invitat: 1st Annual Congress of the Argelian Society of Oncology “ Update in the treatment of 1) bone marrow toxicity 2) antiemetics“ Arger (Argel) 02/04/2011
- 3rd International Congress of Contemporary Oncology. Títol: “Can we optimize the use of Monoclonal Antibodies in Oncology? ”, Poznan, Poland, April 14-16, 2011.
- Conferenciant convidat per la Sociedad de Hematología de la República Dominicana: Títol: “Myelodisplastic Syndromes” i “ Erythropoietin Safety. EPO receptors”29/04/2011.
- Conferenciant convidat per The South African Society of Medical Oncology (SASMO) and the South African Society of Clinical Radiation Oncology (SASCRO), Plenary Session: New Concepts in Cancer Biology: Cancer Stem Cell-Inflammation and Cancer and, a debate “Several recent trials have shown that in certain patients with cancer who were treated with ESAs mortality was increased from disease progression and thromboembolic events. Should we still use Epo?”, Sun City, Johannesburg, Sud-Àfrica 23-27 August, 2011.
- Conferenciant invitat: Annual Congress of the Mexican Society of Oncology, Century XXI : Safety of Erpoetins, Erythropoietin receptors and blood transfusion update”, Riviera Maya, Mèxic, Setembre 2011
- Conferenciant invitat: “Cancer Stem Cell” “ Current management of neutropenia”, Teheran University Medical School, Teheran (Iran): Juliol 2012
- Conferenciant invitat: “Current management of neutropenia ” “Update in management of chemotherapy induced anemia and in blood transfusions”, Bogotà (Colombia) Agost 2012.
- Intravenous iron : supplement or substitute to ESAs? Societat Internacional d’Oncologia i Marcadors Tumorals (ISOBM) Congress, October, 13-17, 2012 (Jerusalem, Israel).
- Tratamientos anti-angiogénicos en cáncer. Universidad de Quito. Ecuador. Enero 2013
- Conferenciant invitat : Congrés Anual d’Hematologia Venezolà “Síndromes Mielodisplásicos”, Isla Margarita (Venezuela), Març 2013
- Conferenciant invitat: Congrés Anual Mexicà d’Hematologia i Transfusions “Efectes Inmunològics de les transfusions sanguinees” i “Tractament de l’anemia induida per la quimioteràpia amb ferro endovenós”, Acapulco (Mèxic), Juny 2013

## 12.- MEMBRE DE SOCIETATS PROFESSIONALS

1975-	Membre, Academy of Medicine Sciences of Catalonia, Spain
1979-1988	Membre, American College of Physicians
1983-	Membre, The New York Academy of Sciences
1985-	Membre, Washington University Alumni Association

1986-	Membre, American Association of University Professors
1986-	Membre, Sigma Xi Scientific Research Society
1986-	Membre, American Society of Hematology
1987-	Membre, American Association for Advancement of Science
1988-	Membre, American Federation for Clinical Research
1988-	Membre, American College of Physicians (FACP)
1989-	Membre, National Institutes of Health (NIH) Alumni Assoc.
1989-	Membre, U.S.A. Spanish Scientists Association (ALDEEU)
1992-	Membre, American Society of Immunologists
1992-	Fellow, New York Academy of Medicine
1994-	Membre, North American Society for Neuroimmunomodulation
1994-	Membre, Spanish Society of Hematology and Hemotherapy
1995-	Membre, Experimental Society of Hematology
1996-	Membre, International Hippocratic Foundation of the Island of Kos (IHFK)
1996-	Membre, History of Medicine Society of New Jersey
1997-	Membre, American Society of Clinical Oncology
1998-	Membre, International Cytokine Society
1999-	Membre, Spanish Society of Medical Oncology (SEOM)
2002-	Membre, American Association Cancer Research (AACR)
2004-2006	President, Acadèmia de Ciències Mèdiques de Catalunya i Balears, Secció Oncologia (Academy of Medical Sciences of Catalonia and Mallorca)
2005-	Membre, European Society Medical Oncology (ESMO)
2005-2006	Membre, International Jury, Galien Awards
2005-	Membre, Societat Espanyola de Recerca en Cancer (ASEICA)
2010-2012	Vocal, Junta de la Societat Espanyola de Recerca en Cancer (ASEICA)
2010-	Membre, 'Acadèmic Corresponent' per la Reial Academia Medicina de Catalunya

### 13.- LÍNIES DE RECERCA

---

1. Paper del gen (PPT-I/TAC) en càncer
2. Papers dels neurotransmissors, neuropèptids en la tumorogènesi.
3. Mecanismes de metàstasis (càncer de mama, pròstata)
4. Regulació de la hematopoiesi per neuropèptids/neurotransmissors i factors neurotròfics.

### 14.- RELACIÓ DE BEQUES CONCEDIDES

---

1. Foundation of University of Medicine and Dentistry of New Jersey.  
Grant #26-87 "Studies of Bone Marrow Failure in the Acquired Immunodeficiency Syndrome"  
Principal Investigator  
July 1986 - June 1987 (extended June 1989)  
Direct Costs: \$24,250.00
2. New Jersey State Commission on Cancer Research  
"Identification of Predictive Markers in Chronic Myelogenous Leukemia"  
Principal Investigator  
July 1987 - June 1989 (extended June 1990) Direct Costs: \$76,272.00

3. The Ruth Estrin Goldberg Memorial for Cancer Research  
"Production of Monoclonal Antibodies Against a Junction Fragment of the bcr-abl 210 protein in Chronic Myelogenous Leukemia"  
Principal Investigator  
July 1988 - July 1989  
Direct Costs: \$15,000.00
4. National Institutes of Health (NIH) RO1 A1/HL 29328  
"Defective Erythropoiesis in AIDS with M Avium Complex"  
Principal Investigator  
Dec 1989 - Nov 1992 (extended November 1993)  
Direct Costs: \$349,014.00
5. National Institutes of Health (NIH) RO1 HL45692-01A1  
"Clinical Trial Sickle Cell Anemia- Subcontract Johns Hopkins University"  
Co-Principal Investigator  
April 1991 - March 31, 1996  
Direct Costs: \$209,852.00
6. National Institutes of Health (NIH) RO1 HL45692-01A1  
"Clinical Trial Sickle Cell Anemia- Follow up"  
Co-Principal Investigator  
April 1996 - March 31, 2001  
Direct Costs: \$38,907.76
7. National Institutes of Health (NIH)-RO1 HL54973  
"Effects of the Neuropeptide Substance P on Hematopoiesis"  
Principal Investigator  
May 1, 1995 - April 30, 1998  
Direct Costs: \$568,453.00
8. National Institutes of Health, R29 HL57675-01  
"Regulation of neurokinin receptors in bone marrow stroma"  
PI: Pranela Rameshwar, PhD, Division of Hematology  
Investigador Col.laborador  
July 1, 1996 - June 30, 2001  
Direct Costs: \$349,925
9. Foundation of the University of Medicine and Dentistry of New Jersey, #31-97  
"Cloning of the preprotachykinin I gene"  
PI: Pranela Rameshwar, PhD, Division of Hematology  
Collaborator  
July 1, 1996 - June 30, 1997  
Direct Costs: \$22,801.00
10. Ruth Estrin Goldberg Memorial for Cancer Research  
"Relevance of the preprotachykinin-I peptides in breast cancer: Role in metastasis and interventions with bone marrow stroma"  
PI: Pranela Rameshwar, PhD, Division of Hematology  
Collaborator  
July 1, 1998 - June 30, 1999  
Direct Costs: \$10,000.00
11. Institute of Health Carlos III. FISS 00/0679.

**“Role of PPT-I gene in breast cancer metastasis ”**

Principal Investigator: Pedro Gascón, PhD, Division of Medical Oncology  
2000-2003

Direct Costs: 17.250.000 pts (\$ 98,760)

12. Institute of Health Carlos III. FISS PI041353

“Effect of integrins and neuropeptides in cancer development”

Principal Investigator: Pedro Gascón, PhD, Division of Medical Oncology  
2004-2007

Direct Costs: 59.800€

13. Cellex Fundation

“The role of tachykinins in breast cancer formation”

Principal Investigator  
2006-2009

Direct Costs: €360.000 euros

15. Cellex Fundation

“La célula stem tumoral: estudios moleculares sobre mecanismos de metástasis”

2009-2013

Direct Costs: 360.000€

16. Institute of Health Carlos III. FISS PI080022

Mechanisms of transactivation of ErbB family members in breast cancer: a role for tachykinins and the neoneurogenesis. Principal Investigator: Pedro Gascón, PhD, Division of Medical Oncology

2009-2011

Direct Costs: 71.635€

17. Cellex Fundation

Medical Oncology, Hospital del Mar and Hospital Clinic (Barcelona)

2009-2011

Direct Costs: 919.800€

18. UMDNJ-New Jersey Medical School

SPONSOR: NIH

Mesenchymal stem cells in Breast Cancer quiescence in Bone Marrow

Investigador Principal: Pranela Rameshwar, MD, PhD

AMOUNT: \$1,874,400

START DATE: 12/1/10

Consultor: Dr. Pere Gascón

19. UMDNJ-New Jersey Medical School

SPONSOR: NIH

A multi-chamber system of neurons and bone marrow functions towards investigations into early neuroimmune regulation

Investigador Principal: Pranela Rameshwar, MD, PhD

AMOUNT: \$1,933,200

START DATE: 4/1/11

Consultor: Dr. Pere Gascón

20. - Institute of Health Carlos III. FISS PI12/01706

Inflammation and breast cancer: neuronal influence and pro-inflammatory neuropeptides in the tumoral progression through the modulation of the stem cell phenotype.

Principal Investigator: Pedro Gascón, PhD, Division of Medical Oncology  
2013-2015  
Direct Costs: 108.900€

#### 15.- RECERCA CLÍNICA. ASSAJOS CLÍNICS

---

1. Mecanismes de les metàstasis
2. Angiogènesi i nous tractaments antiangiogèncis en càncer
3. Ús dels anticossos monoclonals en càncer
4. Anèmia i càncer: patofisiologia i tractament

#### 16.- PATENTS

---

1. A human Preprotachykinin Promoter Gene. Inventors: Pranela Rameshwar and Pedro Gascon (NJMS-97-16; Identification number: 0714201-97-0004)
2. Method of reducing fibrosis. Inventors: Pranela Rameshwar and Pedro Gascon (NJMS-97-17; Identification number: 0714201-97-0007)
3. Novel Method for Quantitating Neuropeptides. Inventors: Pranela Rameshwar and Pedro Gascon (NJMS-97-23; Identification number: 0714201-97-0008)
4. Neuropeptides and Neurotransmitters: New Category of Hematopoietic/Immune Regulators-Growth Factors. Inventors: Pranela Rameshwar and Pedro Gascon (NJMS-97-24; Identification number: 0714201-97-0006)
5. Tachykinin autocrine loop in breast cancer: Inventors: Vanessa Almendro and Pere Gascón-Universitat de Barcelona. Identification number: PCT/ES2009/000191

#### 17.- EXPERIÈNCIA DOCENT

---

- 1974-1975 Instructor in Pharmacology. Barcelona University Medical School, Spain
- 1981-1984 Lecturer, NIH-FAES Hematology Course, Bethesda, Maryland
- 1984-1985 Assistant in Medicine, Washington University School of Medicine St. Louis Missouri.
- 1985-1989 Co-director Hematology/Oncology Fellowship Program, UMDNJ-NJ Medical School

1985-1999	Internal Medicine Board Review Course, University Hospital House Staff and Students Teaching
1989-1999	Adjunt Professor, Rutgers University, Department of Biology
1989-1995	Director, Hematology-Oncology Fellowship Program, UMDNJ-NJ Medical School
1999-	Director, Medical Oncology Fellowship Program
2001-2007	Profesor Asociado, Barcelona Medical School, Barcelona University
2002-	Coordinator, Clinical Oncology , Barcelona Medical School
2003-	Co-director Masters Course in Breast Cancer (Senology), Barcelona Medical School
2003-	Annual lecturer, Department of Biology, University of Barcelona
2007-	Professor Titular, Barcelona Medical School, Barcelona University
2011	Habilitació per a Catedràtic d'Universitat

#### **18.- PRINCIPALS RESPONSABILITATS EN ÀREA HOSPITALÀRIA**

---

1985-1999	Physician in Chief, once a month
1985-1995	Medical Consultant for the Center for Molecular Medicine and Immunology (CMMI)
1989-1995	Attending in Medicine, Hematology and Medical Oncology
1989-1994	Director, Chemotherapy Unit
1995-1999	Attending in Hematology and Medical Oncology.

1999-Present Director, Division of Medical Oncology, Clinic University Hospital, Barcelona.

#### **19.- PRINCIPALS RESPONSABILITATS ADMINISTRATIVES**

---

1985-1999	Director, Division of Hematology
1989-1990	Principal Investigator, Eastern Cooperative Oncology Group (ECG) UMD-New Jersey Medical School
1989-1992	Acting Director, Division Medical Oncology
1992-1994	Director, Division of Hematology - Oncology
1994-1995	Cap de Servei d'Hematologia i Hemoteràpia de l'Hospital de Cruces de la Seguretat Social, Barakaldo, Biscaia.
1994-1999	Director, Division of Hematology
1996-1999	Director, Sickle Cell Clinical Center

1999- Director, Division of Medical Oncology, Clínic University Hospital, Barcelona.

## 20.- MEDICINA PRIVADA

---

1986-1999 University Professors Association, 90 Bergen Street, Suite 4500,  
Newark, New Jersey

1999- Barnaclinic, Clinic Hospital Doctors Association, 170 Villarroel, Barcelona

## 21.- PUBLICACIONES

---

1. Plans ME, Gascon P, Garcia-Valdecasas F: Accion de adrenergicos indirectos en el bazo perfundido in situ. Anales de Medicina 53:1457-1459, 1977.
2. Puig MM, Gascon P, Musacchio JM: Polipeptidos con actividad narcotica. Anales de Medicina 53:1291-1299, 1977.
3. Puig MM, Gascon P, Craviso GL, Bjur RA, Matsueda G, Stewart JM, Musacchio JM: The effect of enkephalin analog on the guinea pig ileum and rat brain opiate receptor. Arch Int Pharmacodyn 225:69-80, 1977
4. Puig MM, Gascon P, Craviso GL, Musacchio JM: Endogenous opiate receptor ligand: Electrically induced release in the guinea pig ileum. Science 195:419-420, 1977.
5. Puig MM, Gascon P, Musacchio JM: Liberacion de encefalinas por estimulacion nerviosa en el ileo aislado de cobra. Anales de Medicina 53:1360-1370, 1977.
6. Puig MM, Gascon P, Musacchio JM: Endorphin release: Cross tolerance to morphine. Eur J Pharmacol 45:205-206, 1977.
7. Puig MM, Gascon P, Musacchio JM: Electrically induced opiate-like inhibition on the guinea pig ileum: Cross tolerance to morphine. J. Pharm Exp Therapy 206:298-302, 1978.
8. Ghiselli G, Schafer EJ, Gascon P, Brewer HB: Type III hyperlipoproteinemia associated with apolipoprotein E deficiency. Science 214:1239-1241, 1981
9. Gascon P, Ley TL, Toltzis RJ, Bonow RD: Spontaneous subarachnoid hemorrhage simulating acute transmural myocardial infarction. Am Heart J. 105:511, 1983.
10. Greco B, Bielory L, Stephany D, Hsu S, Gascon P, Nienhuis A, Young N: Antithymocyte globulin reacts with many normal cell types. Blood 62:1047-1054, 1983.
11. Gascon P, Zoumbos N, Young N: Immunological abnormalities in multiple transfused patients. Ann Int Med 100:173-177, 1984.

12. Lawley TJ, Bielory L, Gascon P, Yancey KB, Young NS, Frank MM: A prospective clinical and immunologic analysis of patients with serum sickness. *N Eng J Med* 311:1407-1413, 1984
13. Zoumbos N, Gascon P, Young N: The function of lymphocytes in normal and suppressed hematopoiesis. *Blut* 48:1-9, 1984.
14. Zoumbos N, Gascon P, Djeu J, Young N: Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo. *Proc Natl Acad Sci* 82:188-192, 1985.
15. Gascon P, Zoumbos N, Scala G, Young N: Lymphokine abnormalities in aplastic anemia. Implications for the mechanism of action of ATG. *Blood* 65:407-413, 1985.
16. Doversen M, Gascon P, Trost S, Hammer J, Goodman S, Noronha A, O'Shannessy D, Brady R, Quarles R: Murine monoclonal antibodies to the myelin associated glycoprotein react with large granular lymphocytes of human blood. *Proc Natl Acad Sci* 82:552-555, 1985.
17. Lawley TJ, Bielory L, Gascon P, Yancey KB, Young N, Frank MM: A prospective sequential study of serum sickness in man. *J Invest Dermatol* 85:1295-1325, 1985.
18. Zoumbos N, Gascon P, Djeu J, Trost S, Young N: Circulating activated suppressor T lymphocytes in aplastic anemia. *N Engl J Med* 312:257-265, 1985.
19. Lawley TJ, Bielory L, Yancey KB, Young N, Gascon P, Frank MM: Serum sickness. *N Engl J Med* 312:1327-1328, 1985.
20. Gascon P, Zoumbos N, Young N: Analysis of natural killer cells in aplastic anemia. *Blood* 67:1349-1355, 1986.
21. Bielory L, Gascon P, Lawley T, Nienhuis A, Frank MM, Young N: Serum sickness and hematopoietic recovery with antithymocyte globulin in bone marrow failure patients. *Br J Haematol* 63:729-736, 1986.
22. Raefsky E, Gascon P, Gratwohl A, Speck B, Young N: Biological and immunological characterization of ATG and ALG. *Blood* 68:712-719, 1986.
23. Bielory L, Gascon P: Bone marrow failure: Immunological implications and treatment modalities. *Ann Allergy* 56:114-116, 123-125, 1986.
24. Platanias L, Gascon P, Bielory L, Nienhuis A, Young N: Lymphocyte phenotype and lymphokine alterations following anti-thymocyte globulin (ATG) therapy of aplastic anemia. *Br J Haematol* 66:437-443, 1987.
25. Bielory L, Gascon P, Lawley TJ, Young N, Frank MM: Human serum sickness: A prospective clinical, immunological and immunopathological analysis of 35 patients treated with anti-thymocyte globulin. *Medicine* 67:40-57, 1988.
26. Bielory L, Holland C, Gascon P, Frohman L: Neurosarcoid and uveitis: Treatment with low dose cyclosporine A. *Trans Proc* 20,(suppl. 4):158-162, 1988.
27. Kurtzman GJ, Gascon P, Caras M, Cohen B, Young N: B19 Parvovirus replicates in circulating cells of acutely infected patients. *Blood* 71:1448-1454, 1988.

28. Benn P, Grossman A, Soper L, Halka K, Eisenberg A, Gascon P: A rare restriction enzyme site polymorphism in the breakpoint cluster region (BCR) of chromosome 22. Leukemia 2:760-762, 1988.
29. Gascon P, Scala G: Decreased Interleukin-1 production in aplastic anemia. Am J Med 85:668-674, 1988.
30. Metha K, Gascon P, Tannir N, Lombardo J, Robboy S: Impaired Bone Marrow in AIDS. NJ Med 86:623-627, 1989.
31. Bielory L, Eckman I, Gascon P: Regulation of IgE production: Isotope class switching by lymphokines. Immuno Aller Prac 11:289-291, 1989.
32. Grossman A, Silver RT, Arlin A, Coleman M, Camposano E, Gascon P, Been PA: Fine mapping of chromosome 22 breakpoints within the breakpoint cluster region (bcr) implies a role for bcr exon 3 in determining disease duration in chronic myeloid leukemia. Am J Hum Genet 45:729-739, 1989.
33. Sathe S.S, Gascon P, Lo W, Reichman LB: Severe anemia is an important negative predictor for survival with disseminated *M. Avium*-intracellular in acquired immunodeficiency syndrome. Am Rev Resp Dis 142:306-312, 1990.
34. Golderberg DM, Sharkey RM, Goldenberg H, Hall TC, Murthy S, Gascon P, Swayne LC: Monoclonal antibody therapy of cancer: The new frontier. NJ Medicine, 87;11:913-918, 1990.
35. Janniger C, Gascon P, Schwartz R, Hennessey P, Lambert: Erythroderma as the initial presentation of AIDS. Dermatologica 183:143-145, 1991.
36. Schwartz R, Helmold ME, Janniger C, Gascon P: Sign of Leser - Trelat with a metastatic mucinous adenocarcinoma. Cutis 46:258-260, 1991.
37. Rameshwar P, Gascon P, Ganea D: Immunoregulatory effects of neuropeptides. Stimulation of IL-2 production by substance-P. J Neuroimmunol 37:65-74, 1992.
38. Metha K, Gascon P, Robboy S: The gelatinous bone marrow (serous atrophy) in patients with AIDS: Evidence of excess sulfated glycosaminoglycans. Arch Pathol Lab Med 116:504-508, 1992.
39. Taylor UD, Bardeguez AD, Iglesias N, Gascon P: Idiopathic myelofibrosis in pregnancy. A case report and review of the literature. Am J Obstet Gynecol 167:38-39, 1992
40. Rameshwar P, Gascon P: Release of IL-1 and IL-6 from human monocytes by antithymocytes globulin. Requirement for de novo synthesis. Blood 80:2531-2538, 1992
41. Lin TZ, Svetic A, Ganea D, Rameshwar P, Gascon P, Gause W, Raveche E: Cytokines in NZB CD5+B clones. Ann NY Acad Sci 3:651-681, 1992.
42. Gascon P, Sathe S, Rameshwar P: Impaired erythropoiesis in the acquired immunodeficiency syndrome with disseminated *Mycobacterium Avium* Complex. Am J Med 94:41-48, 1993.
43. Rameshwar P, Ganea D, Gascon P : In vitro stimulatory effect of substance P on hematopoiesis. Blood 81:391-398, 1993.

44. Sharkey RM, Goldenberg DM, Murthy S, Pinsky H, Vagg R, Pawlyk D, Siegel J, Wong GY, Gascon P et al: Clinical evaluation of tumor targeting with high-affinity, anticarcinoembryonic-antigen-specific, murine monoclonal antibody, MD-14. *Cancer* 71:2082-2096, 1993.
45. Rameshwar P, Gascon P, Ganea D: Stimulation of IL-2 production in murine lymphocytes by substance P and related tachykinins. *J Immunol* 151:2484-2496, 1993.
46. Rameshwar P, Ganea D, Gascon P: In vitro stimulatory effect of substance P on hematopoiesis. *Blood* 81:391-398, 1993.
47. Rameshwar P, Gascon P: Induction of IL-3 and GM-CSF by substance P on bone marrow cells is partially mediated through the release of IL-1 and IL-6. *J Immunol* 152:4044-4054, 1994.
48. Rameshwar P, Denny T, Stein D, Gascon P: Increased release of fibrogenic cytokines, IL-1 and TGF- $\beta$ , is partially mediated via the CD44 molecule in myelofibrosis. *J Immunol* 153:2819-2830, 1994.
49. Charache S, Terrin ML, Moore RD et al: Effect of Hydroxyurea on frequency of painful crises in Sickle Cell Anemia. *N. Engl J Med* 332:1317-1322, 1995.
50. Charache S, Terrin ML, Moore RD, et al: Design of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. *Controlled Clinical Trials* 16:432-446, 1995.
51. Rameshwar P, Gascon P: Induction of the neuropeptide Substance P (SP) and its receptor by c-kit ligand in bone marrow stroma. Implication for neuro-hematopoietic regulation. *Blood* 86:482-490, 1995.
52. Roy M, Gascon P, Giuliani D: Macular flow velocity in sickle cell disease. Relationship to red cell density. *Br J Ophthalmol* 79:742-745, 1995.
53. Rameshwar P, Chang V, Gascon P: Implication of CD44 in adhesion-mediated overproduction of TGF- $\beta$  and IL-1 in monocytes from patients with bone marrow fibrosis. *Br. J Haematol* 93:22-29, 1996.
54. Rameshwar P, Gascon P: Neurokinin-A inhibits granulocyte-macrophage colony formation mostly through the release of soluble factor(s) in bone marrow stroma. *Blood* 88:98-106, 1996.
55. Rameshwar P, Denny T, Gascon P: HIV-1 p24 mediates granulopoietic suppression in vitro. Implication of a putative p24 receptor in bone marrow stroma. *J Immunol* 157:4244-4250, 1996.
56. R.A. Schwartz, M.A. Gallardo, R. Kapila, P. Gascon, J Herscu, I. Siegel and W.C. Lambert: Bacillary angiomatois in an HIV seronegative patient on systemic steroid therapy *Br J Dermatol* 135:982-987, 1996.
57. Rameshwar P, Poddar A, Zhu G, Gascon P: Receptor induction regulates the synergistic effects of substance P with IL-1 and PDGF on the proliferation of bone marrow fibroblasts. *J Immunol* 158:3417-3424, 1997.
58. Charache S, Barton FB, Moore RD et al: Fetal Hemoglobin, hydroxyurea, and sickle cell anemia: Clinical Utility of a hemoglobin "switching" agent. *Medicine* 75:300-326, 1997.

59. Rameshwar P, Gascon P: Hematopoietic Modulation by the Tachykinins. *Acta Haematol* 98:59-64, 1997.
60. Martin H. Steinberg, Shi-Hong Lu, Franca B. Barton, Michael L. Terrin, Samuel Charache, George J Dover and the Multicenter Study of Hydroxyurea: Fetal hemoglobin in sickle cell anemia: Determinants of response to hydroxyurea. *Blood* 89:1078-1088, 1997.
61. Rameshwar P, Poddar A, Gascon P. Hematopoietic regulation mediated by interactions among the neurokinins and cytokines. *Leukemia Lymphoma* 28:1-10, 1997.
62. Rameshwar P, Chang VT, Thacker Usha, Gascon P: Systemic TGF-beta in patients with bone marrow fibrosis. Pathophysiological implications. *Am J Hematol* 59:133-142, 1998.
63. Qian J, Haider A, Teli T, Tuan T, Gascon P, Rameshwar P. Effects of SP(1-4) on cobblestone-forming cells. Implications for endopeptidases as hematopoietic regulators. *Proceedings 10th International Congress of Immunology*. Talwar GP, Nath I, Ganguly NK and Rao KVS editors. Monduzzi Editore, Bologna, Italy, p.575-581, 1998.
64. Bhagat N, Goldberg NF, Gascon P, Bell W, Haberman J, Zarbin MA: Central retinal vein occlusion: report of two familial cases. *Eur J Ophtalmol* 9: 181-195, 1999.
65. Schwartz RA, Cohen JB, Watson RA, Gascon P, Ahkami RN, Ruszczak Z, Halpern J, Lambert WC. Penile Kaposi's sarcoma with penile lymphoedema. *Br J. Dermatol* 142: 153-156, 2000.
66. Singh D, Joshi D, Hameed M, Qian J, Gascon P, Maloof PB, Rameshwar P: Constitutive expression of the preprotachykinin-I and neurokinin receptors in human breast cancer cells. Implications for therapeutic intervention. *Proc Natl Acad Sci* 97:388-393, 2000.
67. Gascon P, Qian J, Joshi DD, Teli T, Haider A, Rameshwar P. Effects of Preprotachykinin-I peptides on hematopoietic homeostasis. Implications for bone marrow endopeptidases. *Ann NY Acad Sci* 917:416-423, 2000.
68. Rameshwar P, Narayanan R, Qian J, Denny T, Gascon P: Role of RelA in adhesion- mediated overactivation of monocytes from patients with idiopathic myelofibrosis. *J Immunol* 165:2271-2277, 2000.
69. Maloof PB, Joshi DD, Qian J, Gascon P, Singh D, Rameshwar P. Induction of PPT-1 and NK-1 by neurohormones in bone marrow stroma. Implications for neuroendocrine-hematopoietic connection *J Neuroimmunol* 112:188-196, 2000.
70. Albiol S, Grau JJ, Pereira A, Reguart N, Gascon P. Epidemic hemolytic-uremic syndrome related to bleomycin. *Haematologica* 86: 10, 2001.
71. Qian J, Yehia G, Molina C, Fernandes A, Donnelly RJ, Anjaria DJ, Gascón P, Rameshwar P: Cloning of human preprotachykinin-I promoter and the role of cAMP response elements in its expression by IL-1 and stem cell factor. *J Immunol*, 166: 2553-2561, 2001
72. Rameshwar P, Joshi DD, Yadav P, Qian J, Gascón P, Chang VT, Anjaria A, Harrison JS, Song X: Mimicry between neurokinin-1 and fibronectin may explain the transport and stability of increased substance P-immunoreactivity in patients with bone marrow fibrosis. *Blood*, 97: 3025-3031, 2001
73. Rameshwar P, Zhu G, Poddar A, Donnelly RJ, Qian J, Ge H, Gascón P: The dynamics of bone marrow stromal cells in the proliferation of multipotent hematopoietic progenitors by

- substance P: An understanding of the effects of a neurotransmitter on the differentiating hematopoietic stem cell. *J Neuroimmunol* 121:22-31, 2001.
74. Joshi DD, Dang A, Yadav P, Qian J, Bandari PS, Chen K, Donnelly R, Castro T, Gascón P, Haider A, Rameshwar P: Negative feedback on the effects of stem cell factor on hematopoiesis is partly mediated through neutral endopeptidase activity on substance P: a combined functional and proteomic study. *Blood* 98:2697-2706, 2001.
75. Reguart N, Gascon P. Factores de crecimiento hematopoyéticos. Indicaciones clínicas. *Med Clínica* 116:390-395, 2001.
76. Reguart N, Maurel. J, Gascón P. Tratamiento complementario y alternativo a la cirugía en las metástasis hepáticas del cáncer colorrectal. *Gastroenterol Hepatol*, 24:210-217, 2001
77. Rameshwar R, Gascón P, Bandari PS, Joshi DD, Fernandes A, Dang A. Structural similarity between the bone marrow extracellular matrix protein and neurokinin I could be the limiting factor in the hematopoietic effects of substance P. *Can J Phys Pharm*. 80: 475-481, 2002
78. Rameshwar P, Gascón P, Oh H, Denny T, Zhu G, Ganea D. Vasoactive intestinal peptide (VIP) inhibits the proliferation of bone marrow progenitors through the VPAC1 receptor. *Experimental Haematol* 30:1-9, 2002
79. Bandari PS, Qian J, Yehia G, Seegopal HP, Harrison JS, Gascón P, Fernandes H, Rameshwar P. Differences in the expression of neurokinin receptor in neural and bone marrow mesenchimal cells: implications for neuronal expansion from bone marrow cells. *Neuropeptides* 35:1-9, 2002
80. Muñoz M, Nadal C, Gascón P. Mecanismos de las metástasis del cáncer de mama. *Rev. Oncol.* 4 suppl 2:1-17, 2002
81. Ayra V, Gascón P, Kihiczak G. Actinic purpura: chronic solar damage with trauma. *J Med* 33: 275-281, 2002
82. Rameshwar P, Oh HS, Yook C, Gascón P, Chang VT. Substance P-Fibronectin-Cytokine interactions in myeloproliferative disorders with bone marrow fibrosis. *Acta Haematol* 109: 1-10, 2003
83. Mellado B, Vela MC, Gutierrez L, Colomer D, Castel T, Estapé J, Gascón P. Tyrosine mRNA in blood of patients with melanoma treated with adjuvant interferon. *J Clin Oncol* 20: 4032-4039, 2002
84. Galán M, Viñolas N, Colomer D, Soler G, Muñoz M, Longarón R, Ventura P-J, Gascón P, Estapé J. Detection of occult breast cancer cells by amplification of CK19 mRNA by reverse-transcriptase-polymerase chain reaction: Role of surgical manipulation. *Anticancer Res* 22: 2877-2884, 2002
85. Soriano A, Castells A, Lacy AM, Ayuso C, Ayuso JR, Conill C, Delgado S, Fuster J, Garcia-Valdecasas JC, Gines A, Martin M, Maurel J, Miquel R, Molla M, Vilana R, Castellvi-Bel S, Elizalde JI, Pinol V, Pellise M, Biete A, Gascon P, Pique JM. Evaluation of the efficacy and efficiency of a multidisciplinary unit for the treatment of patients with colorectal cancer. *Gastroenterol Hepatol Dec;25(10):579-84*, 2002

86. Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascón P, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. *Annals Oncol* 14: 29-35, 2003
87. Bandari P, Qian J, Yehia G, Joshi D, Maloof P, Potian J, Oh H, Gascon P, Harrison J, Rameshwar P. Hematopoietic growth factor inducible neurokinin-1 type (HGF1N): a transmembrane protein that is similar to neurokinin-1 interacts with substance P. *Regulatory Peptides* Mar 28;111(1-3):169-78, 2003
88. Rameshwar P, Oh HS, Yook C, Gascon P, Chang VT. Substance P-fibronectin-cytokine interactions in myeloproliferative disorders with bone marrow fibrosis. *Acta Haematol*;109 (1):1-10, 2003
89. Montagut C, Marmol M, Rey V, Reguart N, Ordi J, Pahissa J, Rovirosa A, Gascón P, Mellado B. Activity of chemotherapy with carboplatin plus paclitaxel in a recurrent mesonophysis. Adenocarcinoma of the uterine corpus. *Gynecologic Oncol* 90: 458-461, 2003
90. Albanell J, Codony J, Rovira A, Mellado B, Gascon P. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. *Adv Exp Med Bio*. 532: 253-268, 2003.
91. Albanell J, Gascón P. Pharmacodynamics and tolerabilities of EGFR-targeted therapies. *Signal* 4, Issue 2: 7-13, 2003
92. Rameshwar P, Sundararajan S, Gascón P. Defect in the lymphoid compartment might account for lymphoid-mediated development of Pure Red Cell Aplasia. *Clin Immunol* 108: 248-256, 2003
93. Reguart N, Gascon P. Novedades en factores de crecimiento. *Rev Cancer* 18 (supl.1): 92-94, 2004
94. Albanell J, Muñoz M, Gascon P. The EGFR as a molecular target for innovative therapies. *Rev Oncol* 6:12-21, 2004
95. Soriano-Izquierdo A, Castells A, Pellisé M, Ayuso C, Ayuso JR, Caralt TM, Fernández-Esparrach G, Sanz MA, García-Criado A, Martín M, Maurel J, Miquel R, Bombí JA, Gascón P, Biete A, Piqué JM, Fernández Cruz L, Navarro S. Registro hospitalario de tumoraciones pancreáticas. Experiencia del Hospital Clínic de Barcelona. *Gastroenterol Hepatol* 27(4): 250-255, 2004
96. Rao G, Patel PS, Idler SP, Maloof P, Gascon P, Potian J, Rameshwar P. Facilitating role of preprotachykinin-1 gene in the integration of breast cancer cells within the stromal compartment of the bone marrow: A model of early cancer progression. *Cancer Res* 64: 2874-2881, 2004
97. Reguart N, Viñolas N, Casas F, Gimferrer JM, Agustí C, Molina R, Martin-Richard M, Sanchez-Reyes A, Gascón P. Integrating concurrent navelbine and cisplatin to hyperfractionated radiotherapy in patients with locally advanced NSCLC treated with platinum and gemcitabine induction chemotherapy. Feasibility and activity results. *Lung Cancer* 45: 67-75, 2004

98. Grau JJ, Domingo J, Mellado B, Albanell J, Gascón P. Low thymidylate synthase expression in the primary tumor predicts favorable clinical outcome in resected gastric cancer patients treated with adjuvant tegafur. *Oncology* 66:226-233, 2004
99. M. Martin-Richard, M. Muñoz, J. Albanell, L. Colomo M. Bellet, M. J. Rey., J. Tabernero., C. Alonso., A. Cardesa, P. Gascon, P. L. Fernandez. Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy. *Oncology* 66: 388-394, 2004
100. Pujade-Lauraine E, Gascón P. The burden of anaemia in patients with cancer. *Oncology* 67 (suppl 1): 1-4, 2004
101. Ludwig H, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascón P, et al. The European Cancer Anaemia survey (ECAS): a large, prospective survey defining the prevalence, incidence, and treatment of anemia in cancer patients. *Eur J Cancer* 40: 2293-2307, 2004
102. Blackwell K, Gascon P, Sigounas G, Jolliffe L. rHuEPO and improved treatment outcomes: potential modes of action. *The Oncologist* 09 Suppl 5:41-7, 2004
103. Cortesi E, Gascón P, Henry D, Littlewood T, Milroy R, Pronzato P, Reinhardt U, Shasha D, Thatcher N, Wilkinson P. Standard of care for cancer-related anemia: improving hemoglobin levels and quality of life. *Oncology* 68 (suppl 1): 22-32, 2005
104. Albanell J, Gascon P. Small Molecules with EGFR-TK Inhibitor Activity. *Curr Drug Targets* 6:259-74, 2005
105. Nadal C, Maurel J, Gallego R, Castells A, Longarón R, Marmol M, Sanz S, Molina R, Martin-Richard M, Gascón P. FASs/FASLs ratio: A marker of oxaliplatin-based intrinsic and acquired resistance in advanced colorectal cancer. *Clin Cancer Res* 11(13):4770-4, 2005
106. Domingo-Domènech J., Molina R., Castel T., Montagut C., Puig S., Conill C., Martí R., Vera M., Auge JM., Malvehy J., Grau J.J., Gascon P. and Mellado B. Serum protein S-100 predicts clinical outcome in patients with melanoma treated with adjuvant interferon. Comparison with tyrosinase RT-PCR. *Oncology* 68:341-349, 2005
107. Montagut C, Rovira A, Mellado B, Gascon P, Ross JS, Albanell J. Preclinical andAnd clinical development of the proteasome inhibitor bortezomib in cancer treatment. *Drugs Today (Barc)* 41:299-315, 2005
108. Gonzalez Cao M, Puig S, Malvehy J, Herrero JE, Marti RM, Conill C, Sanchez M, Mellado B, Gascon P, Castel T. Biochemotherapy with low doses of subcutaneous interleukin-2 in patients with melanoma:results of a phase II trial. *Clin Transl Oncol* 7:250-254, 2005
109. Albanell J, Domingo-Domènech J, Grillo-Lopez J, Gascón P. Hypersensitivity reactions to monoclonal antibodies: Clinical implications. *Drug Safety* (in press)
110. Baselga J, Albanell J, Ruiz A, Lluch A, Gascón P, Guillem V, González S, Sauleda S, Marimón I, Tabernero JM, Koehler MT, Rojo F. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. *J Clin Oncol* 10;23(23):5323-5333, 2005
111. Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortes-Funes H, Hitt R, Gascon P, et al. Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-

Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck. J Clin Oncol 20;23(24):5568-5577, 2005

112. Gascón P. Evaluating erythropoietic agents for the treatment of anaemia in the oncology setting. Eur J Cancer. 41:2601-2612, 2005
113. Barrett-Lee P, Bokemeyer C, Gascon P, et al. Management of Cancer-related anemia in patients with breast or gynecologic cancer: New Insights based on results from the european cancer anemia survey. Oncologist 10:743-757, 2005
114. Gascon P, Morère JF. The evolving role of erythropoietic therapy in patients with cancer. Guest editors. Oncology 69 (suppl 2):1, 2005
115. Díaz-Rubio E, Aranda E, Constela M, Guillén V, Cortés-Funes H, Fernández G, Algarra S, Gascon P. Clinical practice guidelines on antiemetics in oncology. Expert Review of Anticancer Therapy vol. 5(5), 2005
116. Domingo-Domenech J, Mellado B, Ferrer B, Truan D, Codony-Servat J, Sauleda S, Alcover J, Campo E, Gascon P, Rovira A, Ross JS, Fernández PL, Albanell J. Activation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapse. Br J Cancer 93:1285-1294,, 2005
117. Gascon P, Ludwig H. Response to the publication: EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 41:2789-2799, 2005
118. González-Cao M, Malvehy J, Martí R, Conill C, Sanchez M, Martin M, Carrera C; Herrero, Joseph b; Gascon P, Mellado B, Castel T, Puig S. Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-[alpha] in patients with metastatic melanoma. Melanoma Research 16(1):59-64, 2006.
119. Barrett-Lee P, Ludwig H, Birgegård G, Bokemeyer C, Gascon P, et al. Independent Risk Factors For Anemia In Cancer Patients Receiving Chemotherapy: Results From The European Cancer Anaemia Survey (ECAS). Oncology 70: 34-48, 2006
120. Codony J, Tapia M, Bosch M, Oliva C, Domingo-Domènech J, Mellado B, Rolfe M, Ross J, Gascón P, Rovira A, Albanell J. Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Mol Cancer Ther 5: 665-675, 2006
121. Montagut C, Tusquets I, Ferrer B, Corominas JM, Bellosillo B, Campas C, Suarez M, Fabregat X, Campo E, Gascón P, Serrano S, Fernández PL, Rovira A, Albanell J. Activation of nuclear factor-kappa B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients. Endocr Relat Cancer 13: 607-616, 2006
122. Almendro V, Gascón P. Inhibitors of angiogenesis. Clin Transl Oncol 8: 475-481, 2006
123. Domingo-Domènech J, Oliva C, Rovira A, Codony J, Bosch M, Filella X, Montagut C, Tapia M, Campàs C, Dang L, Rolfe M, Ross J, Gascón P, Albanell J, Mellado B. Interleukin 6, a Nuclear Factor-KB Target, Predicts resistance to Docetaxel in Hormone-Independent Prostate Cancer and Nuclear Factor-KB Inhibition by PS-1145 Enhances Docetaxel AntitumorActivity. Clin Cancer Res 12: 5578-5586, 2006
124. Birgegård G, Gascón P, Ludwig H. Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY. Eur J Haematol 77(5):378-86, 2006

125. Mellado B, Gascón P. Molecular biology of renal cell carcinoma. Clin Transl Oncol 10: 706-710, 2006
126. Maurel J, Martin-Richard M, Conill C, Sanchez M, Petriz L, Gines A, Miquel R, Gallego R, Cajal R, Ayuso C, Navarro S, Marmol M, Nadal C, Auge JM, Fernández-Cruz L, Gascón P. Phase I trial of gefitinib with concurrent radiotherapy and fixed 2-h gemcitabine infusion, in locally advanced pancreatic cancer, Int J Radiat Oncol Biol Phys 66: 1391-1398, 2006
127. Garcia Y, Mármol M, Gascón P. Los medicamentos recombinantes en oncohematología. Haematologica 91: 3-14, 2006
128. Grau JJ, Monzó M, Caballero M, Carles J, Palmero R, Artells R, Picó C, Gascón P. Expression of cyclooxygenase-2 mRNA in peripheral blood of head and neck cancer patients and in healthy controls. A pilot study. Acta Oto-Laryngologica 127: 71-75, 2007
129. Vincent M, Dranitsaris G, Lau C, Gascón P., Van Belle S, Ludwig H. The development and validation of a prediction tool for chemotherapy-induced anemia in patients with advanced non-small cell lung cancer receiving palliative chemotherapy. Supportive care in cancer 15: 265-272, 2007
130. Maurel J, Nadal C, Garcia-Albeniz X, Gallego R, Carcereny E, Mármol M, Gallardo E, Augé JM, Longarón R, Martínez-Fernandez A, Molina R, Castells A, Gascón P. Serum matrix metalloproteinase 7 (MMP-7) levels identifies poor prognosis advanced colorectal cancer patients. Int J Cancer 121: 1066-1071, 2007
131. Tapia MA, González-Navarrete I, Dalmases A, Bosch M, Rodríguez-Fanjul V, Rolfe M, Ross JS, Mezquita J, Mezquita C, Bachs O, Gascón P., Rojo F, Perona R, Rovira A, Albanell J. Inhibition of the canonical IKK/NFκB pathway sensitizes human cancer cells to doxorubicin. Cell Cycle 6: 2284-2292 , 2007
132. Lipton A, Steger G, Figueira J, Alvarado C, Solal-Celigny P, Body J, de Boer R, Berardi R, Gascon P., et al. Randomized Active-controlled Phase 2 Study of Denosumab Efficacy and Safety in Breast Cancer Patients With Bone Metastases. J Clin Oncol 25: 4431-4437, 2007
133. Domingo-Domènech J, Castel T, Auge JM, Garcia Albeniz X, Conill C, Puig S, Vilella R, Matas J, Malvehy J, Gascón P., Mellado B, Molina R. Prognostic implications of protein S-100β serum levels in clinical outcome of high-risk melanoma patients. Tumor Biology 28: 264-272, 2007
134. Nadal C, Maurel J, Gascón P.. "Is there a genetic signature for liver metastasis in colorectal cancer?" World J Gastroenterol 13: 5832-5844, 2007
135. Gascón P.. The future of molecular markers in cancer: towards a tailored treatment. Med Clinica 129: 775-776, 2007
136. García-Albeniz X, Martinez-Fernandez A, Gascon P.. Combinig targeted therapies. Targeted Oncology 2: 241-252, 2007
137. Domingo-Domènech J, Fernández PL, Filella X, Martínez-Fernández A, Molina R, Fernández E, Alcaraz A, Codony J, Gascón P., Mellado B. Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel. Ann Oncol 19: 269-275, 2008

138. Aapro M, Birgegard G, Bokemeyer C, Cornes P, Foubert J, Gascón P, et al. Erythropoietins should be used according to guidelines. *The Lancet Oncology* 9: 412-413, 2008
139. Albanell J, Montagut C, Jones ET, Pronk L, Mellado B, Beech J, Gascón P, et al. A Phase I study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumors. *Clin Cancer Res* 14: 2726-2731, 2008
140. Gascón, P. Safety update on erythropoiesis stimulating agents: trials within and outside the accepted indications. *The Oncologist* 13: 4-10, 2008
141. Awada A, Albanell J, Canney PA, Dirix LY, Gil T, Cardoso F, Gascón P, Piccart MJ, Baselga J. Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study. *Brit J Cancer* 98: 1500-1507, 2008
142. Lipton A, Steger GG, Figueira J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R, Berardi R, Gascon P, et al. Extended Efficacy and Safety Denosumab in Breast Cancer Patients With Bone Metastases Not Receiving Prior Bisphosphonate Therapy, CCR-07-5234R. *Clin Cancer Res* 14: 6690-6696, 2008
- Con formato: Fuente: 11 pto, Catalán
143. Domingo-Domènech J, Pippa R, Tapia M, Gascón P, Bachs O, Bosch M. Inactivation of NF- $\kappa$ B by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells. *Breast Cancer Res Treat* 112: 53-62, 2008
144. Carcereny E, Viñolas N, Gascón P. Angiogenesis inhibitors in the treatment of non small-cell lung cancer (NSCLC). *Clin Transl Oncol* 10: 198-203, 2008
- 144.145. Cortes J, Di Cosimo S, Climent MA, Cortés-Funes H, Lluch A, Gascón P, Mayordomo JI, Gil M, Benavides M, Cirera LL, Ojeda B, Rodríguez CA, Trigo JM, Vázquez J, Regueiro P, Dorado JF, Baselga J. Non-pegylated liposomal doxorubicin (TLC-D99), paclitaxel and trastuzumab in HER2 overexpressing breast cancer: a multicenter phase I/II study. *Clin Cancer Research* 15: 307-314, 2009
- Con formato: Fuente: 11 pto, Catalán
- 145.146. Mellado B, Codony J, Ribal MJ, Visa L, Gascón P. Molecular biology of androgen-independent prostate cancer: the role of the androgen receptor pathway. *Clin Transl Oncol* 11: 5-10, 2009
- 146.147. Baró E, Carulla J, Cassinello J, Colomer R, Garcia-Mata J, Gascón P, Gasquet JA, Herdman M, Rodríguez CA, Sánchez J, Valentín V. Development of a new questionnaire to assess patient perceptions of cancer-related fatigue: item generation and item reduction. *Value Health* 12: 130-138, 2009
- Con formato: Fuente: 11 pto, Catalán
- 147.148. Soriano-Izquierdo A, Adet AC, Gallego R, Miquel R, Castells A, Pellisé M, Nadal C, López-Boado MA, Maurel J, Bombí JA, Gascón P, Biete A, Piqué JM, Fernández Cruz L, Navarro S. Predicción del pronóstico de los pacientes con adenocarcinoma pancreático resecado con intención curativa mediante el grado histológico y el estadio N patológico. *Medicina Clínica* 132: 163-171, 2009
- 148.149. Gallego R, Codony J, García-Albéniz X, Carcereny E, Longaron R, Olivera A, Tosca M, Auge JM, Gascon P, Maurel J. Serum IGF-IGFBP-3 and MMP-7 levels and acquired chemo-resistance in advanced colorectal cancer. *Endocr Relat Cancer* 16: 311-317, 2009

- | 149.150. Martínez-Fernández A, García-Albéniz X, Pineda E, Visa L, Gallego R, Codony J, Augé JM, Longarón R, Gascón P, Lacy A, Castells A, Maurel J. Serum matrilysin levels predict outcome in curatively resected colorectal cancer patients. Ann Surg Oncol 16: 1412-1420, 2009
- | 150.151. Almendro V, Ametller E, Garcíorecio S, Collago O, Casas I, Augé JM, Maurel J, Gascon P. Increased MMP-7 expression and loss of Fas receptor functionality in colorectal cancer cells: a potential mechanisms of acquired chemoresistance. PLoS ONE 4: 4728, 2009
- | 151.152. Gascón P. Futuro de los marcadores moleculares en cáncer: hacia un tratamiento personalizado. (Editorial) Med Clin 132: 549-550, 2009
- | 152.153. Locatelli F, Gascon P. Is nephrology more at ease than oncology with ESAs? The Oncologist 14 (suppl 1): 57-62, 2009
- | 153.154. Spivak J, Gascon P, Ludwig H. Anemia management in oncology and hematology. The Oncologist 14 (suppl 1): 43-56, 2009
- | 154.155. Vansteenkiste J, Hedenus M, Gascon P, Bokemeyer C, Ludwig H, Vermorken J, Hamilton L, Bridges K, and Pujol B. Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus ≥ 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial. BMC Cancer 9: 311- 323, 2009
- | 155.156. Mellado B, Font A, Alcaraz A, Aparicio LA, Veiga FJG, Areal J, Gallardo E, Hannaoui N, Lorenzo JRM, Sousa A, Fernandez PL, Gascón P. Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer. Brit J Cancer 101: 1248-1252, 2009
- | 156.157. Alberola V, Carrato A, Díaz-Rubio E, Gascón P, González-Baron M, Martin M, Alba E, Cassinello J, Colomer R, Cruz JJ, Barnadas A, Caps C, Casas AM, Carulla J, Constenla M, Gavilà J, Isla D, Massutti B, Provencio M, Rodriguez CA, Sant J, Spanish Society of Medical Oncology: Spanish society of medical oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients. Clin Transl Oncol 11: 727-736, 2009
- | 157.158. Maio M, Mackiewicz A, Testori A, Treftzer U, Ferraresi V, Jassem J, Garbe C, Lesimple T, Guillot B, Gascon P, Gilde K, Camerini R, Cognetti F. Phase II Randomized Study of Thymosin Alpha 1, Interferon Alpha, or Both, in Combination with Dacarbazine in Patients with Malignant Melanoma. J Clin Oncol 28: 1780-1787, 2010
- | 158.159. Rojo F, Gracia E, Villena N, Cruz T, Corominas JM, Corradino I, Cedeño M, Campas C, Bellosillo B, Rovira A, Marsoni S, Gascón P, et al. Pharmacodynamic trial of nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody, in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study. Clin Cancer Res 16: 2474-2482, 2010
- | 159.160. Tusquets I, García-Estevez L, Adrover E, Calvo L, Alvarez I, García-Mata J, Fernandez Y, Margueli M, Segui MA, Rodríguez C, Rodríguez Lescure A, Colomer R, Gascón P, et al. Current controversies in the managament of breast cancer. Clin Transl Oncol 12: 278-286, 2010
- | 160.161. Steinberg M, McCarthy W, et al and investigators of the multicenter study of hydroxyurea in Sickle cell anemia and MSH patients follow-up. The risks and benefits of

long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol 85: 403-408, 2010

- | 161-162. Gascon P, Uwe Fuhr, Fritz Sörgel, Suzanne Einmahl, Sigrid Balser, and Michael Muenzberg. Development of a new G-CSF product based on biosimilarity assessment. Annals Oncol 21: 1419- 1429, 2010
- | 162-163. Almendro V, Garcia-Recio S, Gascón P. Tyrosine kinase receptor transactivation associated to G-protein-coupled receptors. Current Drug Targets 11: 1169-1180, 2010
- | 163-164. Ametller E, Garcia-Recio S, Domiziana C, Mayordomo C, Fernandez-Nogueira P, Carbó N, Pastor-Arroyo E, Gascón P, Almendro V. Tumor promoting effects of CD95 signalling in chemoresistant cells. Mol Cancer 9: 161, 2010
- | 164-165. Gascón P, Pirker R, Mastro del L., Durrwell L. Effects of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Receiving Chemotherapy: Results of a Phase II Study. Annals Oncology 21(10): 2029-2039, 2010
- | 165-166. Hörndl C, Gallego R, Garcia-Albeniz X, Alonso-Espinaco-V, Alonso V, Escudero P, Jimeno M, Ortego J, Codony-Servat J, Hernández-Martos C, Calatrava A, Marín-Aguilera M, Muñoz J, Castellví-Bel S, Castells a, Rubini M, Gascón P, Maurel J. Co-expression of matrix metalloproteinase-7 (MMP-7) and phosphorylated insulin growth factor receptor I (pIGF-1R) correlates with poor prognosis in patients with wild-type KRAS treated with cetuximab or panitumumab. A GEMCAD study. Cancer Biol Ther 11(2): 177-183, 2011
- | 166-167. Ametller E, García-Recio S, Pastor-Arroyo EM, Callejo G, Carbó N, Gascón P, Almendro V. Differential regulation of MMP7 in colon cancer cells resistant and sensitive to oxaliplatin-induced cell death. Cancer Biology & Therapy 11(1):4-13, 2011
- | 167-168. Garcia-Albeniz X, Pericay C, Alonso-Espinaco V, Alonso V, Escudero P, Fernández-Martos C, Gallego R, Gascón P. Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab. Tumour Biol 32: 417-424, 2011
- | 168-169. Font C, Vidal L, Espinosa G, Tàssies D, Monteagudo J, Farrús B, Visa L, Cervera R, Gascon P, Reverter JC. Solid cancer, Antiphospholipid antibodies, and venous thromboembolism. Autoimmun Rev 10: 222-227, 2011
- | 169-170. Gascon P, Aapro , Ludwig H, Rosencher N, Turner M, Macdonald K, Lee C, Muenzberg M, Abraham I. Background and methodology of MONITOR-GCSF, a pharmac-epidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar granulocyte-colony stimulating factor filgrastim. Crit Rev in Oncol Hemat 77: 184-197, 2011
- | 170-171. Gascón P, Aapro M, Ludwig H, Rosencher N, Boccadoro M, Turner M, Macdonald K, Muenzberg M, Abraham I. Update on the MONITOR-GCSF study of biosimilar filgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia in cancer patients: protocol amendments. Crit Rev Oncol Hematol 77: 198-200, 2011
- | 171-172. Baro E, Casinello J, Colomer R, Garcia J, Gascón P, et al. Psycometric properties of the perform questionnaire: a brief scale for assessing patient perceptions of fatigue in cancer. Supportive care in cancer 19(5):657-666, 2011

- | 172.173. Gascón P, Almenárez J, Artal A, Camps C, Fírvida JL, Garrido P, González Larriba JL, Montalar L. Management of lung cancer-associated anaemia: the Spanish Lung Cancer Anaemia Survey (SLCAS). Clin Transl Oncol 13: 328-334, 2011
- | 173.174. Aapro M, Beguin Y, Birgegard G, Gascón P, Hedenus M, Ostenborg A. Too low iron doses and too many dropouts in negative iron trial? J Clin Oncol 29 (17): e525-526 2011
- | 174.175. Mancino M, Ametller E, Gascon P, Almendro V. The neuronal influence on tumor progression. Biochim Biophys Acta. 1816(2):105-118, 2011
- | 175.176. Campayo M, Navarro A, Viñolas N, Tejero R, Muñoz C, Diaz T, Marrades R, Cabanas M, Gimferrer JM, Gascón P, Ramirez J, Monzo M. A dual role for KRT81: a miR-SNP associated with recurrence in non-small-cell lung cancer and a novel marker of squamous cell lung carcinoma. Plos One 6(7): e22509, 2011
- | 176.177. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Wilson H, Miller W, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TS, Humphrey R, Hoos A, Wolchok J. Ipilimumab plus dacarbazine in previously untreated metastatic melanoma. N Engl J Med 364(26):2517-2526, 2011
- | 177.178. Font C, Farrús B, Vidal L, de Caralt TM, Visa L, Mellado B, Tàssies D, Monteagudo J, Reverter JC, Gascon P. Incidental versus symptomatic venous thrombosis in cancer a prospective observational study of 340 consecutive patients. Ann Oncol 22: 2101-2116, 2011
- | 178.179. Aapro M, Gascón P, Dicato M, Hofmann A. Foreword. Oncologist 16 (suppl 3): viii, 2011
- | 179.180. Pérez-Torras S, Vidal-Pla A, Miquel R, Almendro V, Fernández-Cruz L, Navarro S, Maurel J, Carbo N, Gascón P, Mazo A. Characterization of human pancreatic orthotopic tumor xenografts suitable for drug screening. Cell Oncol 34(6):511-521, 2011
- | 180.181. Mayordomo C, Garcia-Recio S, Ametller E, Fernandez-Nogueira P, Pastor-Arroyo E, Vinyals L, Casas I, Gascon P, Almendro V. Targeting of Substance P induces cancer cell death and decreases the steady state of EGFR and Her2. J Cell Physiol 227(4):1358-1366, 2012
- | 181.182. Marín-Aguilera M, Codony-Servat J, Kalko S, Fernández PL, Bermudo R, Buxo E, Ribal MJ, Gascón P, Mellado B. Identification of docetaxel resistance genes in castration-resistant prostate cancer. Mol Cancer Ther 11(2): 329-339, 2012
- | 182.183. Gascón P. Presently available biosimilars in hematology-oncology: G-CSF. Target Oncol, 7 (Suppl 1): 29-34, 2012
- | 183.184. Muñoz Langa J, Gascón P, de Castro J. SEOM clinical guidelines for myeloid growth factors. Clin Transl Oncol 14(7): 491-498, 2012
- | 184.185. Canon JL, Vansteenkiste J, Hedenus M, Gascon P, Bokemeyer C, Ludwig H, Vermorken J, Legg J, Pujol B, Bridges K. Transfusion risk in cancer patients with chemotherapy-induced anaemia when initiating darbepoetin alfa therapy at a baseline haemoglobin level of < 9 g/dL vs 9 to < 10 g/dL vs ? 10 g/dL: An exploratory analysis of a phase 3 trial. Medical Oncologist, 2011 Nov 13. [Epub ahead of print]

- | 185-186. Aapro M, Österborg A, Gascón P, Ludwig H, Beguin Y. Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol 23(8):1954-1962, 2012
- | 186-187. Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG; SAVE-ONCO Investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012 Feb 16;366(7):601-9.
- | 187-188. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011 Dec 29;365(26):2484-96.
- | 188-189. M. Aapro, A. Molassiotis, M. Dicato, I. Peláez, Á. Rodríguez-Lescure, D. Pastorelli, L. Ma, T. Burke, A. Gu, P. Gascon, F. Roila, on behalf of the PEER investigators. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): The Pan European Emesis Registry (PEER). Ann Oncol, 23 (8): 1986-1992, 2012
- | 189-190. Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG, SAVE-ONCO Investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 366(7): 601-609, 2012
- | 190-191. Codony J, Marin-Aguilera M, Visa L, Garcia-Albeniz X, Pineda E, Fernandez PL, Filella X, Gascon P, Mellado B. Nuclear factor-kappa B and Interleukin-6 related docetaxel resistance in castration-resistant prostate cancer. Prostate, 2012 Oct 4. doi: 10.1002/pros.22591.
- | 191-192. Font C, Campayo M, Farrús B, Fernández-Martínez A, Reguart N, Tàssies D, Viñolas N, Reverter JC, Gascón P. Venous thromboembolism in patients with lung cancer: clinical findings and outcome in a prospective observational study. Adv in Cancer: Res & Treat, 2012
- | 192-193. Gascón P. Iron therapy in cancer-induced anemia. Transfusion alternatives in transfusion medicine, doi: 10.1111/j.1778-428X.2012.01171.
- | 193-194. Susana Garcia-Recio, Gemma Fuster, Patricia Fernandez-Nogueira, Eva M. Pastor-Arroyo, So Yeong Park, Cristina Mayordomo, Elisabet Ametller, Mario Mancino, Xavier Gonzalez-Farre, Hege Russnes, Pablo Engel, Domiziana Costamagna, Pedro L. Fernandez, Gascón P; Vanessa Almendro. Substance P/TACR1 autocrine-signaling system contributes to persistent activation of HER2 increasing malignancy and therapeutic resistance in human breast cancer cells. (Cancer Research- under revision)
- | 194-195. Molassiotis A, Aapro M, Dicato M, Gascon P, Novoa SA, Isambert N<sup>6</sup>, Davidson N<sup>7</sup>, Burk T, Gu A<sup>7</sup>, Roila F. Evaluation of pre-treatment risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study. (submitted for publication)

Factor de Impacte (IF): 1168.122

## 22.- ABSTRACTES

---

1. Puig MM, Gascon P, Craviso G, Bjur RA, Stewart JM, Musacchio JM: Effects of enkephalin analog on the guinea pig ileum. Society for Neurosciences. Sixth Annual Meeting, 1976.
2. Musacchio JM, Gascon P Craviso GL, Puig MM: Endorphin release by electrical stimulation. Am. Society for Neurochemistry. Eighth Annual Meeting, 1977.
3. Puig MM, Gascon P, Craviso GL, Musacchio JM: Opiate receptor activation by electrical stimulation: Evidence for endorphin release by nerve stimulation. FASEB, 1977.
4. Gascon P, Humphries RK, Young N: Analysis of immune suppression of murine hematopoiesis by monoclonal antibodies. AFCR, 1982.
5. Gascon P, Young N: Decreased natural killer activity in hypertransfused patients. ASH, 1982.
6. Gascon P, Young N: Decreased natural killer activity in hypertransfused patients. Seventh Meeting, ISH, 1983.
7. Gascon P, Scala G, Djeu J, Young N: Abnormal interleukin production in aplastic anemia. Third Int. Conference on Aplastic Anemia, 1983.
8. Bielory L, Gascon P, Lawley T, Frank M, Young N: Serum sickness during ATG Administration. Third Int. Conference on Aplastic Anemia, 1983.
9. Zoumbos N, Gascon P, Djeu J, Young N: Interferon is the mediator of hematopoietic suppression in vitro and possibly of bone marrow in vivo. ASH, 1983.
10. Bielory L, Gascon P, Lawley T, Frank M, Young N: The relationship of hematopoietic response to serum sickness during anti-thymocyte globulin (ATG) therapy. ASH, 1983.
11. Gascon P, Zoumbos N, Scala G, Moore J, Young N: Lymphokine production in aplastic anemia: Implications for the mechanism of action of anti-thymocyte globulin. ASH, 1983.
12. Bielory L, Gascon P Lawley T, Frank M, Young N, Kaliner, M: Immunoglobulin levels during serum sickness from anti-thymocyte globulin (ATG) therapy. Am Academy of Allergy and Immunology, 1984.
13. Lawley TJ, Bielory L, Gascon P, Yancey KB, Young N, Frank MM: A prospective sequential study of serum sickness in man. AFCR, 1984.
14. Zoumbos N, Gascon P, Djeu J, Young N: Interferon is present in normal bone marrow and in high concentrations in patients with bone marrow failure. FCR, 1984.

15. Djeu JY, Dyer D, Gascon P, Robboy R: Interleukin-2 enhancement of natural killer activity in resting human large granular lymphocytes is independent of the activated T cell IL-2 receptor. Sixteenth International Leukocyte Culture Conference, 1984.
16. Zoumbos N, Gascon P, Djeu J, Trost S, Young N: Circulating activated suppressor cells in aplastic anemia ASH, 1984.
17. Raefsky E, Gascon P, Zoumbos N, Bielory L, Moore J Speck B, Young N: Biological, biochemical and immunological characterization of ATG and ALG. ASH, 1984.
18. Bielory L, Gascon P, Lawley T, Young N, Grank M: Human serum sickness (SS): A clinical and immunological analysis in 35 patients. Int Cong. Allergy and Clin. Immunol. (ICACI), 1985.
19. Platanias L, Gascon P, Bielory L, Zoumbos N, Djeu J, Siegel J, Nienhuis A, Young N: Lymphocyte phenotype and lymphokine alterations following anti-thymocyte globulin (ATG) therapy of aplastic anemia. ASH, 1985.
20. Gascon P, Scala G, Djeu J, Young N: Decreased lymphokine and monokine production in hypertransfused patients. ASH, 1986.
21. Kurtzman G, Ozawa K, Gascon P, Cohen S, Caras M, Young N: Viral DNA in circulating cells of patients acutely infected with B19 parvovirus. ASH, 1986.
22. Bielory L, Gascon P, Young N, Frank M, Lawley T: Characterization of circulating immune complexes (CIC) in human serum sickness (SSX), AAA, 1987.
23. Ciccone R, Sunderam G, Bielory L, Gascon P, Denny T, Reichman L: Correlation of severity and prognosis of tuberculosis with cell mediated immune defects in HIV infection. ATS, 1987.
24. Mehta K, Tannir N, Gascon P, Lombardo J: Altered bone marrow hematopoietic microenvironment in AIDS. ASCP/CAP, 1987.
25. Bielory L, Holland C, Gascon P, Frohman L: Neurosarcoid and uveitis treatment with low dose cyclosporine A. Second Intl Conf on Cyclosporine A, 1987.
26. Bielory, Gascon P: Chronic neutropenia (CN) responsive to antithymocyte globulin (ATG). 44th Ann Congr Am Coll Allergy, 1987.
27. Gascon P, Scala G, Young N: Interleukin-1 in hyper-and hypoproliferative bone marrow disease: monocyte production in myelofibrosis and aplastic anemia. ASH, 1987.
28. Mehta K, Gascon P: Hematopoietic microenvironment of AIDS. USCAP, 1988.
29. Benn P, Grossman A, Soper L, Hall B, Silver R, Coleman M, Arlin Z, Gascon P: Limited heterogeneity of chromosome 22 breakpoints in chronic myelogenous leukemia (CML).ASH, 1988.
30. Benn P, Grossman A, Soper L, Halka K, Eisenberg A, Gascon P: Restriction enzyme fragment length polymorphisms (RFLP's) in the breakpoint cluster region of chromosome 22 can be a complication for DNA probe diagnosis of chronic myeloid leukemia (CML). ASH, 1988.

31. Grossman A, Camposano E, Silver RT, Coleman M, Arlin Z, Gascon P, Benn P: The distribution of chromosome 22 breakpoints in newly diagnosed cases of chronic myeloid leukemia (CML). ASH, 1988.
32. Halka K, Gascon P: Interleukin-1 stimulation of busulfan-treated marrow in long-term cultures. ASH, 1988.
33. Rameshwar P, Yip P, Gascon P: The bone marrow as a target organ for HIV infection. ASH, 1988.
34. Gascon P, Rameshwar P, Sathe S: Studies on the mechanism of AIDS associated anemia. ASH, 1988.
35. Sathe SS, Gascon P, Pinto R, Kapila R, Reichman LB: Anemia is a powerful prognostic indicator for survival in patients with disseminated *M. Avium* (MAI) associated with AIDS. ATS, 1989.
36. Metha K, Benedetti R, Gascon P, Raina S, Studzinski G: bcl-2 oncogene rearrangement in the diagnosis of malignant lymphoma. ASCP/CAP, 1989.
37. Gascon P, Rameshwar P, Jansons KV: "In vitro inhibition of erythropoiesis by *M avium* Complex". ASH, 1989.
38. Rameshwar P, Gascon P: Antithymocyte globulin (ATG) stimulates the production of IL-1 and IL-6 by monocytes. ASH, 1990.
39. Botti A, Gascon P, Kanuga D, Nayak S: Fatal B-19 parvovirus infection in 2 patients doubly heterozygous for hemaglobulins "S" and "C". ASH, 1990.
40. Rameshwar P, Gascon P, Ganea D: Immunoregulatory effects of substance P in a murine thymoma cell line model. Rutgers University, 1990.
41. Rameshwar P, Gascon P, Ganea D: Stimulation of IL-2 Production by Substance-P. FASEB, 1991.
42. Raveche ES, Lin TZ, Guse W, Svetic A, Ganea P, Rameshwar P, Gascon P: Cytokine production by spontaneously arising CD5 + B cell clones of NZB origin. FASEB, 1991.
43. Rameshwar P, Gascon P: Disparity between circulating interferon levels and in vitro interferon induction in AIDS patients. AFCR, 1991.
44. Ganea D, Rameshwar P, Gascon P: Immunoregulatory effects of neuropeptides: Upregulation of IL-2 production in EL-4 cells by substance-P. Keystone Symposia on Molecular & Cellular Biology. Cytokines and their receptors: From clonal to clinical investigation, 1991.
45. Rameshwar P, Gascon P: Antithymocyte Globulin (ATG) induces the production of multiple cytokines by monocytes. NHLBI, 1991.
46. Rameshwar P, Ganea D, Gascon P: In vitro effect of substance-P on myelopoiesis. ASH, 1991.
47. Rameshwar P, Srivastava P, Gascon P: Increased IL-1, IL-6 and active TGF- $\beta$  production by monocytes in myelofibrosis. ASH, 1991.

48. Sharkey RM, Goldenberg DM, Murthy S, Siegel J, Gascon P, Vezza M, Pinsky CM, Hansen HJ, Wong GY: Tumor targeting in patients with a second generation, high-affinity, anti-carcinoembryonic antigen (CEA) murine monoclonal antibody. Society for Biological Therapy Annual Meeting, 1991.
49. Taylor U, Gascon P, Apuzzio J, Bardeguez A: HIV-Associated immune thrombocytopenia in pregnancy. Society of Perinatal Obstetricians (SPO), 1991.
50. Rameshwar P, Scolpino A, Denny T, Gascon P: Antithymocyte globulin (ATG) induces de novo synthesis of multiple cytokines by monocytes. Am Soc Clin Pharm Therap (ASCPT), 1992.
51. Reyes R, Gascon P, Bielory L: Humoral immunodeficiencies associated with thymic disorders. J Allergy Clin Immunol, 1992.
52. Sharkey RM, Goldenberg DM, Murthy S, Gascon P, Izon D, Pinsky CM, Hansen HJ, Wong CY: Clinical investigations with a second-generation, high affinity, anticarcinoembryonic antigen (CEA) murine monoclonal antibody (MN-14; IMMU-14). AACR, 1992.
53. Sharkey RM, Goldenberg DM, Murthy S, Siegel J, Izon D, Gascon P, Pinsky CM, Hansen HJ, Wong GY: Clinical evaluation of a second generation, High-affinity, anticarcinoembryonic antigen (CEA) murine monoclonal antibody (MAb), MN-14. The Society of Nuclear Medicine 39th Annual Meeting, 1992.
54. Rameshwar P, Gascon P: Role of the bone marrow's stroma in substance-P's induction of hematopoiesis. ASH 1992.
55. Rameshwar P, Denny T, Stephens R, Deneve A, Gascon P: Implication of high P24 antigen and reverse transcriptase in AIDS bone marrow. AFCR, 1992.
56. Rameshwar P, Gascon P: Evidence for an autoimmune mechanism in pure red cell aplasia (PRCA). AFCR, 1992.
57. Sharkey RM, Izon D, Gascon P, Levine GM, Vagg R, Ahmad M, Pawlyk D, Siegel JA, Hansen HJ, Goldenberg DM: Phase-I radioimmunotherapy (Rait) with I-131-labeled MN-14F (ab)2, a carcinoembryonic antigen (CEA)-specific, murine monoclonal antibody(Mab). The Society of Nuclear Medicine 40th Annual Meeting, 1993.
58. Rameshwar P, Ganea D, Gascon P: Substance P (SP) induces the production of IL-3 and GM-CSF by human peripheral blood (PB) and bone marrow (BM) mononuclear cells (MNCs). AAI/CIS, 1993.
59. Gascon P, Rameshwar P: Regulatory effects of substance P (SP) on hematopoiesis. Role of the bone marrow (BM) stroma. AAI-CIS-Mucosal Immunol, 1993.
60. Rameshwar P, Gascon P: Vasoactive intestinal peptide (VIP) and substance P (SP) exert opposite effects on in vitro hematopoiesis. Blood 82:489a, 1993.
61. Rameshwar P, Gascon P: CD34+ cells express substance P (SP)-like receptors. Blood 82:10a, 1993.
62. Rameshwar P, Gascon P: Regulation of substance-P (SP)-like receptors in CD34+ cells by cytokines and neurotrophic factors. FASEB, 1993.

63. Rameshwar P, Gascon P: Regulation of substance-P (SP)-like receptors in CD34+ cells by cytokines and neurotrophic factors. FASEB/AAI, 1994
64. Rameshwar P, Keller SE, Niu HL, Gascon P: Monocyte adhesion in myelofibrosis is associated with increased tyrosine phosphorylation and upregulation of CD25 expression. Role of CD44 adhesion molecule. ASH, 1994
65. Rameshwar P, Gascon P: Induction of the neuropeptide substance-P (SP) and its receptor (SP-R) by stem cell factor (SCF) in bone marrow (BM) stroma. Implications for neurohematopoietic regulation. ASH, 1994.
66. Rameshwar P, Gascon P: Hematopoietic regulation by the tachykinins is mediated through opposite effects by neurokinin-1 and 2 receptors. FASEB/AAI, 1995.
67. Rameshwar P, Gascon P: Adhesion-mediated overproduction of fibrogenic cytokines in monocytes as a common mechanism for bone marrow (BM) fibrosis. AFCR, 1995.
68. Rameshwar P, Gascon P: Role of bone marrow (BM) fibroblasts in substance P(SP)-mediated hematopoietic regulation. AAI/9th International Congress of Immunology, 1995.
69. Rameshwar P, Gascon P: Hematopoietic regulation by substance-P (SP) and neurokinin-A (NK-A). Implications for a neuro-hematopoietic communication. International Symposium on Molecular Biology of Hematopoiesis, 1995
70. Rameshwar P, Narayanan R, Denny TN, Stein D and Gascon P: Antisense p65 subunit of NK-KB prevent adhesion of idiopathic myelofibrosis (IMF) monocytes. implication for CD44 expression and TGF- $\beta$  induction. ASH, 1995
71. Rameshwar P and Gascon P: Endogenous endopeptidase and protection of progenitor cells from apoptosis contribute to the hematopoietic regulatory mechanisms exerted by substance P (SP). ASH 1995.
72. Rameshwar P and Gascon P: Products of the preprotachykinin-1 (PPT-I) gene exert similar hematopoietic effects on bone marrow(BM) stem cells and progenitors. Am. Assoc. Immunol., 1996
73. Rameshwar P and Gascon P: Regulation of early hematopoiesis by at least two neuropeptides requires intercellular crosstalk among cells of the bone marrow microenvironment. Int'l Soc. Exp. Hematol., 1996
74. Rameshwar P and Gascon P: Neurokinin-1 The high affinity substance P (SP) receptor is present on erythroid (BFU-E, CFU-E) and granulocytic (CFU-GM) Progenitor. Implication for direct neural effect on CD34+ cells. ASH, 1996.
75. Rameshwar P, Zhu G, and Gascon P: Vasoactive intestinal peptide (VIP) exerts negative hematopoietic effects through the type 1 receptor ASH, 1996.
76. Rameshwar P, Qian J, Gascon P: Constitutive Expression of the Preprotachykinin-I Gene in Breast Cancer Cells. Implication for Therapeutic Intervention. NJCCR/Annual New Jersey Breast Cancer Symposium, 1997.
77. Rameshwar, P, Gascon P, Qian J, Donnelly RJ, Thacker U: Substance P (SP): The Neurotransmitter that Bridges the Neural-Hematopoietic Crosstalk. Society for Neurosciences, 1997.

78. Qian J, Teli T, Haider A, Joshi DD, Rameshwar P, Gascon P: The Prepro-tachykinin-I (PPT-I) Gene Peptides provide their own Hematopoietic feedback. Implications of Endogenous Endopeptidases. ASH, 1997.
79. Rameshwar P, Qian J, Haider, A, Teli T, Joshi DD, Tran T, Gascon P: Feedback Regulation during Immune Cell Development by Preprotachykinin-I (PPT-I) Peptide Fragment. Implication for Endogenous Endopeptidases. FASEB/AAI, 1998.
80. Singh D, Qian J, Maloof P, Quinlan D Jr., Gascon P, Rameshwar P: Implication of Neuroimmune Modulators, Neurokinins, in Breast Cancer Development. FASEB/AAI, 1998.
81. Singh D, Hameed M, Gascon P, Qian J, Rameshwar P: Constitutive expression of preprotachykinin-I in breast biopsies. Implications for metastasis to the bone marrow (BM). New Jersey Commission on Cancer Research, 1998.
82. Qian J, Gascon P, Maloof P, Rameshwar P: Preprotachykinin-I (PPT-I) peptides: Neurotransmitters that mediate neural-hematopoietic crosstalk. Seventeenth Summer Symposium in Molecular Biology, Penn State, 1998.
83. Rameshwar P, Haider A, Teli T, Tuan T, Qian J, Gascon P: Effects of Prepro- tachykinin-I (PPT-I) peptides on cobblestone-forming cells (CAFC). Implications for stem cell protection. 10th International Congress of Immunology, 1998.
84. Qian J, Gascon P, Maloof P, Rameshwar P: Expression of the neurotransmitter gene, PPT-I, in bone marrow. Implications for neural-hematopoietic cross-talk. Society for Neuroscience, 1998.
85. Rameshwar P, Gunanayagam P, Qian J, Narayanan R, Singh D, Gascon P. Bone marrow fibrosis: is there a common immune-mediated mechanism? ASH, 1998.
86. Qian J, Rameshwar P, Singh D, Gascon P. Cloning of the human preprotachykinin-I (PPT-I) promoter. A tool for understanding cytokine neuropeptide interactions in hematopoietic regulation. ASH, 1998.
87. Gascon P, Qian J, Teli T, Haider A, Rameshwar P. Effects of Preprotachykinin-I peptides on hematopoietic homeostasis. Implications for bone marrow endopeptidases. The 4th International Congress of the International Society for Neuroimmunomodulation 6:402, 1999.
88. Qian J, Gascón P, Molina CA, Yehia G, Donnelly RJ, Rameshwar P. Cloning of human preprotachykinin-I (PPT-I) promoter: Analysis of cAMP responsive element (CRE). UMDNJ-Grad. Sch. of Biomed. Sci, 1999.
89. Rameshwar P, Qian J, Gascon P. Role of the neural-hematopoietic axis in breast cancer metastasis to the bone marrow. Society for Neurosciences, 1999.
90. Gascon P, Rao G, Rameshwar P, Qian J, Aniaria DJ. Mechanism of early integration of breast cancer in the bone marrow. Role of preprotachykinin-I (PPT-I). ASH, 1999.
91. Rao G, Qian J, Fernandes A, Gascon P, Rameshwar P. Breast Cancer (BC)-mediated changes in gene expression in bone marrow (BM) stroma: Implications for early integration of BC to BM. AACR, 2000.

92. Nadal C, Maurel J, Ginés A, Conill C, Reguart N, Martin M, Gascón P. Downstaging de la radioterapia preoperatoria en adenocarcinoma de recto evaluado prospectivamente con ecoendoscopia. FESEO, 2000
93. Rameshwar P, Gascon P, Qian J, Fernandes A, Chang V, Devashish A, McCall L, Joshi DD. Increased levels of substance P (SP) is transported in myelofibrosis by complexing to fibronectin (FN). Intl. Soc Exp Haematol (ISH), 2000.
94. Gascon P, Rameshwar P, Qian J, Fernandes A, Fernandes A, Anjaria D, McCall L, Joshi DD. Dysregulation of preprotachykinin-I in patients with myeloproliferative disorders: Novel concepts in the development of bone marrow fibrosis. Intl. Conference "Towards an understanding of the molecular basis of myeloproliferative disorders", 2000.
95. Rameshwar P, Gascon P, Qian J, Joshi DD., Yadav P. The confounds of molecules homologous to neurokinin receptors in tachykinin-mediated hematopoietic regulation. Intl. Tachykinin Conference, 2000.
96. Qian J, Yehia G, Molina CA, Rao G, Fernandes A, Gascón P, Rameshwar P. Breast cancer (BC) cells induce preprotachykinin-I (PPT-I) and other hematopoietic regulators in bone marrow (BM) stroma: Relevance to BM disruption. New Jersey Commission on Cancer Researc., 2000.
97. Rao G, Caputo FJ, Qian J, Yadav P, Donnelly RJ, Harrison JS, Bandari P, Gascon P, Rameshwar P. Overexpression of preprotachikinin-I (PPT-I) in breast cancer (BC):implication for metastasis to the bone marrow (BM). Intl. Tachykinin Conference, 2000.
98. Qian J, Gascon P, Molina CA, Yehia G, Fernandes A, Donnelly RJ, Rameshwar P. Regulation of human preprotachykinin-I expression and tissue-specific influence. Intl Tachykinin Conference, 2000.
99. Vinolas N, Casas F, Soler G, Martín-Richard M, Navalpotro B, Belda J, Gascon P. Front-Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC) with Alternating Chemotherapy (CT) and Concurrent Radiotherapy (RT): Phase II. ASCO 2000
100. Grau JJ , Albiol S, Martin M, Vinolas N, Gascon P, Pera M, Fuster J, Palacin A, Bombi A. Survival Impact of Adjuvant Chemotherapy Based on Mitomycin (MMC) Alone or Associated with Tegafur (TG) in Resected Gastric Cancer. Analysis of 326 Patients. ASCO 2000
101. Bandari P, Qian J, Harrison JS, Caputo FJ, Rameshwar P, Gascon P. Hematopoietic growth factor inducible neurokinin-1 type (HGFN) gene encodes a novel transmembrane glycoprotein that is induced by cytokines and neurotrophic factors in bone marrow (BM) stroma but is constitutively expressed in differentiated cells. ASH, 2000.
102. Rameshwar P, Bandari P, Qian J, Yehia G, Seegopal H, Gascon P. Sequences within the 5' untranslated region of neurokinin-1 receptor that represses its expression in bone marrow stroma could be reversed by cytokines through activation of NF- $\kappa$ B. An analysis of neurogenic inflammation. FASEB/AAI, 2001.
103. Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascón P, et al. Fixed-dose, single-administration SD/01 vs daily Filgastrim in patients with high-risk breast cancer. ASCO Proceedings, 2001.
104. Mellado B, Castel T, Colomer D, Fontanillas M, Viñolas N, Reguart N, Estapé J, Gascón P. Tyrosinase mRNA in the blood of patients with melanoma as a surrogate marker of the efficacy of adjuvant Interferon therapy. ASCO, 2001.

105. Rameshwar P, Gascón P, Qian J, Bandari P, Dang A, Donnelly R. Hematopoietic regulation by peptides from the preprotachykinin-I gene is regulated by cytokines and endogenous endopeptidases. Peptide Receptors. From gene to therapy, 2001.
106. Martin-Richard M, Fernandez P, Rey MJ, Muñoz M, Reguart N, Gascon P. Expression of Cyclin D1, p53 and HER2 neu in Advanced Breast Carcinomas. ASCO 2001
107. Sastre J, Reguart N, Alfonso R, Maurel J, Gascón P, Díaz-Rubio E. Administración quincenal de CPT-11 + 5-FU en infusión continua (5-FUIC) de 48 horas a altas dosis como tratamiento de primera linea en una población no seleccionada de pacientes (pts) con cáncer colorrectal avanzado (CCRA). SEOM, 2001.
108. Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortes-Funes H, Gascon P, et al. Cetuximab (C225) plus cisplatin/carboplatin is active in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) refractory to another platinum-based regimen. ASCO, 2002.
109. Trigo J, Climent MA, Gil A, Lluch A, Horredo J, Gascón P et al. Cardiac safety and activity of a phase I study of 3-weekly myocet in combination with weekly herceptin and paclitaxel in HER2-positive (HER2+) locally advanced or metastatic breast cancer (LA/MBC): definition of maximum tolerated dose (MTD). ASCO, 2002.
110. Ludwig H, Barret-Lee PJ, Gascon P, et al. European Cancer Anaemia Survey (ECAS) defines factors surrounding anemia in thousands of adult cancer patients. ASCO 2002
111. Domingo-Domenech J, Montagut C, Molina T, Castel T, Fontanillas M, Gascon P, Mellado B. Rising serum S100 levels during adjuvant interferon therapy predict high risk of relapse in patients with melanoma. ASCO 2002
112. Martin-Richard M, Munoz M, Fernandez PL , Colomo L, Bellet M, Rey MJ, Gascon P. Overexpression of topoisomerase II $\alpha$  as a predictive factor of response to doxorubicin-based chemotherapy in locally advanced breast. ASCO 2002
113. López Martin A, Constela M, Martín Algarra S, Salinas P, Massuti B, Gascón P, et al. Iressa in advanced non-small cell lung cancer (NSCLC) patients progressed to chemotherapy. ASCO 2003
114. Gascón P et al. El tratamiento con Erbitux <sup>TM</sup> (Cetuximab), una nueva esperanza para enfermos con cáncer colorrectal metastásico. ASCO 2003
115. Domingo-Domenech J, Molina R, Montagut C, Castel T, Martin-Richard M, Gascon P, Mellado B. Predictive value of S100 luminoimmunometric assay (LIA) and tyrosinase RT-PCR in melanoma patients treated with adjuvant interferon. ASCO 2003
116. J. Baselga, J. Albanell, A. Ruiz, A. Lluch, P. Gascon, S. Gonzalez, V. Guillen, S. Sauleda, S. Averbuch, F. Rojo. Phase II and tumor pharmacodynamic study of gefinitib (ZD1839) in patients with advanced breast cancer. ASCO 2003
117. M. Gonzalez Cao, S. Puig, J. Malvehy, M. Martin-Richard, R. Marti, C. Conill, R. Rull, A. Vilalta, T. Castel, P. Gascon. Biochemotherapy with temozolamide (TMZ) and IL2 subcutaneous (sc) in metastatic melanoma (MM). ASCO 2003

118. JJ. Grau, Domingo-Domenech J, Montagut C, Mellado B, Pera M, Albanell J, Gascón P. Thymidylate synthase predicts the outcome in gastric cancer patients treated with adjuvant tegafur in a randomized trial. ASCO 2003
119. Nadal C, Maurel J, Gallego R, Mármol M, Sanz S, Molina R, Gascón P FASs/FASLs ratio: a marker of chemoresistance in advanced colorectal cancer (CRC). ASCO 2004
120. Domingo-Domenech JM, Codony J, Tapia M, Filella X, Alcover J, Rovira A, Gascon P, Albanell J, Mellado B. High serum interleukin-6 levels predicts resistance to chemotherapy in hormone-independent prostate cancer. Proc Amer Assoc Cancer Res, 2004
121. Gunnar Birgegård, Heinz Ludwig, Johan Nortier, Dirk Schrijvers, Gascón P. Independent risk factors for anemia in patients with lymphoma/myeloma are defined by logistic regression modeling: results from the european cancer anaemia survey (ECAS). EHA, 2004
122. Montagut C, Mellado B, Mármol M, Santos M, Domingo-Domenech J, Garcia A, Ramón y Cajal S, Puig-Tintoré LM, Gascón P, Ordi J. Immunohistochemical staining for p16INK4A selectively detects human papillomavirus-related premalignant and malignant vulvar lesions. ASCO 2004
123. Marmol M, Pomes J, Muñoz M, Macho J, Blasco J, Combalia A, Farrus B, Verger E, Tomàs X, Gascon P. Vertebroplastia in patients with tumour injury of the vertebral body; therapeutic effect and short term complications. ASCO 2004
124. Palmero R, Grau JJ, Monzó M, Molina R, Gascón P. Serum VEGF (sVEGF) has no predictive value in advanced head and neck cancer (H&NC) patients (pts) treated with weekly paclitaxel. ESMO 2004
125. Grau JJ, Carles J, Monzó M, Palmero R, Artells R, Domingo-Domenech J, Navarro A, Amat M, Fabregat X, Gascon P. Expression of cyclooxygenase-2 mRNA (COX2-mRNA) in peripheral blood (PB) of head and neck cancer patients (HNC) and healthy controls (HC). ASCO 2004
126. Tapia M, Codony-Servat J, Domingo-Domenech J, Ferrer F, Fernandez PL, Ross JS, Rolfe M, Gascon P, Rovira A, Albanell J. Activity of bortezomib, a proteasome inhibitor, in breast cancer cells: association with negative estrogen receptor and IKK/NF-kB expresión. Procc. ASCO (3169), 2005
127. Gascon P. Basal sFAS/sFASL ratio and FAS polymorphisms as a prognostic marker, in advanced colorectal carcinoma patients (ACRC), treated with oxaliplatin-based chemotherapy. Procc. ASCO (3631), 2005
128. Domingo-Domenech J, Rovira A, Codony-Servat J, Filella X, Montagut C, Ross JS, Rolfe M, Gascon P, Albanell J, Mellado B. Nuclear Factor-kB (NF-kB)/Interleukin-6 (IL-6) pathway activation confers resistance to docetaxel (D) in hormone-independent prostate cancer (HIPC). Procc. ASCO (9630), 2005.
129. Carulla J, Valentín V, Rodríguez CA, Gascón P, García-Mata J, Colomer R, Cassinello J, Baró E, Gasquet JA, Sánchez J. The development of a new scale for assessing patient perceptions of cancer-related fatigue (CRF). ESMO 2006

130. Carcereny E, Nadal C, Maurel J, Augé J, Almendro V, Gallego R, Longaron R, Marmol M, Gascon P. Role of matrix metalloproteinase-7 (MMP-7) and soluble forms of FAS (sFAS) and FASL (sFASL) in the development of chemoresistance in patients with advanced colorectal carcinoma (ACRC), treated in first and second line therapy. ASCO 2006
131. Vincent M, Dranitsaris G, Clemons M, Verma S, Lau C, Gascon P, Van Belle S, Ludwig H. The development of a prediction tool for chemotherapy-induced anemia in patients with advanced non-small cell lung cancer (NSCLC) palliative receiving chemotherapy. ASCO 2006
132. Domingo-Domenech J, Gallardo E, Filella X, Fernandez E, Fernandez PL, Gascon P, Mellado B. Serum c-erbB-2 ectodomain (ECD) correlates with immunohistochemical c-erbB-2 expression and predicts an aggressive clinical outcome in hormone-independent prostate cancer (HIPC) patients (pts) treated with docetaxel (D). ASCO 2006
133. Almendro V, Maurel J, Augé J, Laus G, Domingo-Domenech J, Fernández E, Gascon P. Role of metalloproteinase-7 in oxaliplatin acquired resistance in colorectal cancer cell lines. ASCO 2006
134. Gascon P, Barrett-Lee PJ, for the ECAS Investigators. Prevalence of anemia in cancer patients not receiving antineoplastic treatment (ANT): Data from the European Cancer Anaemia Survey (ECAS). ASCO 2006
135. Garcia-Albeniz X, Maurel J, Nadal C, Gascon P. Use of MMP-7 as a prognosis marker in advanced colorectal cancer. ASCO 2007
136. Domingo-Domenech J, Martinez-Fernandez A, Garcia-Albeniz X, Fernández P, Filella X, Gascon P, Mellado B. Correlation of serum interleukin-6 (IL-6) levels with immunohistochemical p65/nuclear factor- $\kappa$ B (NF- $\kappa$ B) expression and prediction of the clinical outcome of hormone-independent prostate cancer patients (HIPC) treated with docetaxel (D). ASCO 2007
137. Gascón P, García-Mata J, Colomer R, Cassinello J, Carulla J, Valentín V, Rodríguez CA, Baró E, Gasquet JA. Validation of the perform questionnaire, a new questionnaire to assess the patient perception of cancer-related fatigue. ECCO 2007
138. Reverter JC, Font C, Monteagudo J, Corbella M, Freire C, Pijoan J, Gascon P, Tassies MD. Importancia de los polimorfismos genéticos relacionados con la adhesión y función procoagulante de las micropartículas en las trombosis asociadas al cancer. XLIX Reunión Nacional de la Asociación española de hematología y hemoterapia (AEHH). XXIII Congreso Nacional de la Sociedad española de trombosis y hemostasia (SETH). Pamplona 25-27 de octubre de 2007.
139. Font C, Visa L, Tassies MD, Monteagudo J, Gascon P, Reverter JC. Enfermedad tromboembólica venosa en el paciente oncológico: estudio prospectivo observacional de 136 pacientes consecutivos. XLIX Reunión Nacional de la Asociación española de hematología y hemoterapia (AEHH). XXIII Congreso Nacional de la Sociedad española de trombosis y hemostasia (SETH). Pamplona 25-27 de octubre de 2007.
140. Casals FJ, Font C, Caralt TM, Escolar G, Gascon P. Trombosis venosa asintomática del segmento cavaíaco en enfermos de cáncer. XLIX Reunión Nacional de la Asociación española de hematología y hemoterapia (AEHH). XXIII Congreso Nacional de la Sociedad española de trombosis y hemostasia (SETH). Pamplona 25-27 de octubre de 2007.

141. J. C. Reverter, C. Font, J. Monteagudo, M. Corbella, C. Freire, J. Pijoan, P. Gascon, D. Tassies. Cancer and venous thromboembolism: Role of genetic polymorphisms in selectins and tissue factor. XXIst Congress of the International Society on Thrombosis and Haemostasis, July 6-12, 2007 in Geneva, Switzerland.
142. Visa L, Font C, Farrús B, Tassies D, Caralt TM, Gascón P, Reverter JC. Incidental vs symptomatic venous thrombosis in cancer patients. ASCO 2008
143. Gallego R, Garcia-Albéniz J, Codony J, Nadal C, Carcereny E, Longaron R, Augé J, Gascón P, Maurel J. Correlation of matrilysin levels and IGF-1/IGFBP-3 ratio with acquired chemo-resistance in advanced colorectal cancer (ACRC). ASCO 2008
144. Vargas M, Valduvieco I, Almendro V, Domingo-Domènech J, Ametller E, Pons F, Herreros A, Muñoz M, Gascón P, Farrús B. Radiosensitivity enhancement by dual HER-1/2 inhibitor (GW572016) in SKBR3 human breast carcinoma HER-2+ cell line. ASCO 2008
145. García-Albéniz X, Pericay C, Alonso V, Escudero P, Fernández-Martos C, Augé J, Gallego R, Tosca M, Gascón P, Maurel J. Pharmacodynamic study of soluble FAS (sFASL), in patients (pts) with advanced colorectal cancer (ACRC) after irinotecan and cetuximab treatment in third-line therapy: results of HCB-05-01 trial. ASCO 2008
146. Petit A, García-Albéniz X, Gaspa A, Mellado B, Gascón P, Mallofré C. Vascular expression of PDGFR- $\beta$  isoform as a predictor of survival in non-metastatic clear renal cell carcinoma. ASCO 2008
147. Cassinello H, Carulla J, Valentín V, Rodríguez CA, Gascón P, García-Mata J, Colomer R, Baró E, Gasquet JA on behalf of the PERFORM Study Group. Determining the clinical significance of the improvement in health-related quality of life (HRQoL) measures in oncology patients. ASCO 2008
148. Grau JJ, Font C, Visa L, Monteagudo J, Gascón P, Reverter JC, Tassies D. Cancer and venous thromboembolism: role of genetic polymorphisms in selectins and tissue factor. ASCO 2008
149. Ychou M, Hohenberger W, Thezenas S, Navarro M, Gascón P, Bokemeyer C, Shacham-Shmueli E, Rivera F, Kwok-Keung Choi C, Santoro A. Randomized phase III trial comparing infused 5-fluorouracil/folinic acid (LV5FU) versus LV5FU + irinotecan (LV5FU+IRI) as adjuvant treatment after complete resection of liver metastases from colorectal cancer (LMCRC). (CPT-GMA-301). ASCO 2008
150. Carcereny E, Castellvi-Bel S, Alonso V, Garcia-Albéniz X, Muñoz J, Gallego R, Hondler C, Castells A, Gascón P, Maurel J. EGFR polymorphisms as predictors of clinical outcome in patients with advanced colorectal cancer (ACRC) treated with cetuximab and panitumumab. ASCO 2008
151. Garcia S, Almendro V, Ametller E, Callejo G, Collazo O, Gascón P. Regulation of MMP7 expression during the acquisition of oxaliplatin resistance in colon cancer cells. AACR, San Diego 2008
152. Ametller E, Garcia S, Callejo G, Collazo O, Gascón P, Almendro V. Activation of survival pathways by CD95 in cells resistant to oxaliplatin. AACR, San Diego 2008
153. Garcia-Albéniz X, Martínez-Fernandez A, Visa L, Pineda E, Tagliapietra A, Campayo M, Gallego R, Codony J, Nadal C, Gascón P, Maurel J. Matrilysin-based score for predicting recurrence in curatively resected colorectal cancer (CRC). Gastrointestinal ASCO 2009

154. Gascon P, Ludwig H, Vermorken J, Hamilton L, Pujol B. The effect of darbepoetin alfa on haemoglobin levels and transfusion requirements in chemotherapy-treated patients with different tumour types: exploratory data from a phase III study. MASCC, Viena 2009
155. Garcia-Recio S, Ametller S, Fernandez PL, Costamagna D, Mayordomo-Tella C, Fernández-Nogueira P, Muñoz M, Gascón P, Almendro V. Substance P regulates ErbB receptors activation and expression inducing phenotypical alterations in breast carcinoma cells. AACR, Denver, Colorado, 2009
156. Gascón P, Viqueira A, Fernández G, González ML, Polo E, Díaz N, Sánchez F, Blancas M<sup>a</sup> I, Morales S, Rodríguez A. Estudio Estrella: incidencia e impacto del estreñimiento inducido por opioides. SEOM, Barcelona 2009
157. Fernández-Nogueira P, Costamagna D, Ametller E, Garcia-Recio S, Mayordomo C, Pastor-Arroyo EM, Muñoz M, Gascón P, Almendro V. Characterization of new receptors implicated in the acquisition of resistance to trastuzumab and lapatinib. 6º Simposio Internacional de Oncología Traslacional. ASEICA, 2010
158. Garcia-Recio S, Ametller E, Fernandez PL, Costamagna D, Mayordomo C, Fernandez-Nogueira P, Pastor-Arroyo EM, Muñoz M, Gascón P, Almendro V. Proinflammatory mediators: substance P modulation of ErbB receptors induces changes in breast cancer cells to a more aggressive phenotype. 6º Simposio Internacional de Oncología Traslacional. ASEICA, 2010
159. Mayordomo C, Ametller E, Fernandez-Nogueira P, Garcia-Recio S, Casas I, Pastor-Arroyo EM, Gascón P, Almendro V. New antibody therapy for the treatment of breast cancer. 6º Simposio Internacional de Oncología Traslacional. ASEICA, 2010
160. Canon JLR, Vansteenkiste JF, Hedenus M, Gascón P, et al. An exploratory analysis of transfusion risk when initiating darbepoetin alfa (DA) therapy at baseline hemoglobin (Hb) <9 g/dl vs ≥ 10 g/dl in patients (pts) with chemotherapy-induced anemia (CIA). ASCO 2010
161. Gascón P, Henry DH, Fleishman A, Borenstein JE. Design of an ongoing randomized study on the long-term safety and efficacy of darbepoetin alfa (DA) administered 500 mcg every three weeks (Q3W) to non-small cell lung cancer (NSCLC) patients (pts) with anemia concomitant with chemotherapy (ACC). ASCO 2010
162. Ludwig H, Gascón P, Aapro M, Rosencher N, Turner M, Song M, MacDonald K, Lee C, Muenzberg M, Abraham I. Background, objectives, and methodology of MONITOR-GCSF - a pharmaco-epidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar filgrastim. European Haematological Association (Barcelona, June 2010).
163. Aapro M, Gascón P, Ludwig H, Rosencher N, Turner M, Song M, MacDonald K, Lee C, Muenzberg M, Abraham I. Design of a European pharmacoepidemiological study of biosimilar filgrastim in the prophylaxis of febrile neutropenia (MONITOR-GCSF). Supportive Care in Cancer. Multinational Association for Supportive Cancer Care (Vancouver, June 2010)
164. Clinical development of a new biosimilar granulocyte colony-stimulating factor. EAHP, Nice 2010
165. Garcia-Recio S, Mayordomo C, Ametller E, Fernandez-Nogueira P, Pastor-Arroyo E, Costamagna D, Fernandez PL, Munoz M, Gascón P, Almendro V. Changes in breast cancer

cell phenotype induced by the proinflammatory mediator substance P. CPID (Cell Press Inflammation in Disease Conference) Lisboa, 2010

166. Puig M, Gimenez A, Gómez-Caro A, Gascón P, Reguart N, Alcaraz J. Caveolin-1-independent fibroblast activation in lung squamous cell carcinoma. Nature-CNIO Symposium 2010
167. Puig M, Gimenez A, Gómez-Caro A, Gascón P, Alcaraz J, Reguart N. Caveolin-1-independent fibroblast activation in lung squamous cell carcinoma. IDIBELL Cancer Conference on Metastasis and Angiogenesis, Barcelona 2011.
168. Gimenez A, Puig M, Gabasa M, Lugo R, Galgoczy R, Xaubet A, Navajas D, Gascón P, Reguart N, Alcaraz J. Abnormal tissue hardening in lung fibrosis and cancer. Congreso Sociedad Biofísica de España, Murcia 2011.
169. Puig M, Gimenez A, Gómez-Caro A, Gascón P, Alcaraz J, Reguart N. Caveolin-1-independent fibroblast activation in lung squamous cell carcinoma. Biannual World Conference on Lung Cancer, Amsterdam 2011.
170. Puig M, Gimenez A, Lugo R, Galgoczy R, Gascón P, Reguart N, Navajas D, Alcaraz J. Stromagenesis in non-small cell lung cancer. CIBERES, Bunyola 2011.
171. Campayo M, Feliz L, Gascón P, Pereira V, Reguart N, Reig O, Victoria I. Eficacia del talcaje con cisplatino en el tratamiento del derrame pericárdico maligno. SEOM, Málaga 2011
172. Gascon P. Can we optimize use of monoclonal antibodies in oncology? 3<sup>rd</sup> Congress of Contemporary Oncology, 2011
173. Henry D, Nag S, Smakal M, Cárdenas J, Fleishman A, Inamdar S, Gascón P. The 20070782 protocol for a randomized phase 3 trial on the long-term safety of every three week (Q3W) darbepoetin alfa (DA) in non-small cell lung cancer (NSCLC) patients (pts) with chemotherapy-induced anemia (CIA). ASCO 2011
174. Visa L, Grau JJ, Caballero M, Pineda E, Ortega V, Gaba L, Gascón P. Analysis of patient age and adjuvant chemotherapy (ACh) as predictor of survival in patients (pts) with resected gastric adenocarcinoma (RGA). ASCO 2011
175. Henry DH, Nag SM, Smakal M, Cardenas JS, Fleishman A, Inamdar S, Gascon P. The 20070782 protocol for randomized phase 3 trial on the long-term safety of every three week (Q3W) darbepoetin alfa (DA) in non-small cell lung cancer (NSCLC) patients (pts) with chemotherapy-induced anemia (CIA). ASCO 2011
176. Campayo M, Navarro A, Viñolas N, Tejero R, Muñoz C, Diaz T, Marrades R, Cabanas ML, Gimferrer JM, Ramirez J, Gascon P, Monzo M. A single nucleotide polymorphism (SNP) in a microRNA (miRNA)-binding site of KRT81 and time to recurrence (TTR) in surgically resected non-small-cell lung cancer (NSCLC) patients (p). ASCO 2011
177. Visa L, Grau JJ, Caballero M, Pineda E, Ortega V, Gaba L, Gascon P. Analysis of patient age and adjuvant chemotherapy (ACh) as predictor of survival in patients (pts) with resected gastric adenocarcinoma (RGA). ASCO 2011
178. Gaba L, Ortega V, Font C, Farrús B, Tàssies D, Reverter JC, Gascon P. Venous thromboembolism in outpatients with cancer receiving chemotherapy for solid tumors. ASCO 2011

179. Ortega V, Gaba L, Font C, Reig O, Victoria I, Visa L, Pineda E, Oleaga L, Gascon P. Central nervous system venous thrombosis in cancer. Frequency and clinical characteristics in a prospective observational study of 339 patients. ASCO 2011
180. M. Aapro, A. Molassiotis, M. Dicato, P. Gascon, L. Ma, T. Burke, F. Roila, on behalf of the PEER Investigators. Effect of guideline consistent chemotherapy prophylaxis (GCCP) on chemotherapy-induced nausea and vomiting (CINV): the pan european emesis registry (PEER). MASCC/ISSSO, Atenes (Greece) 2011
181. Fernández-Nogueira P, Rye I, Costamagna D, Ametller E, Garcia-Recio S, Mancino M, Vinyals L, Pares M, Pastor-Arroyo EM, Fuster G, Gascón P, Borresen-Dale AL, Russnes HG, Almendro V. Identification of phosphor-receptors implicated in the acquisition of resistance to anti-HER2 therapies in breast cancer. Advances in Breast Cancer Research: Genetics, Biology and Clinical Applications (AACR) San Francisco, 2011
182. Puig M, Lugo R, Giménez A, Galgoczy R, Genís S, Ramírez J, Gómez-Caro A, Gascón P, Alcaraz J, Reguart R. Abnormal abundance of senescent fibroblasts in the tumor stroma of non-small cell lung cancer patients. AACR, Chicago 2012.
183. Gascon P, Hermine O, Hoffmann C, Aapro M. IV iron usage in chemotherapy-induced anemia: an observational, pan-european study. European Hematology Association (EHA), Amsterdam 2012
184. LR. Félix, V. Pereira, M. Monzo, C. Munoz, P. Fuste, P. Gascon, A. Torrents, L. Vidal. Single nucleotide polymorphisms analysis of BRAC and ERCC1 as predictor of recurrence after chemoradiation for cervical cancer patients. ASCO 2012
185. Gascon P. Use of biosimilar G-CSF for prevention of chemotherapy induced neutropenia: pooled analysis of clinical usage studies. ESMO 2012
186. Gascón P. Anaemia-related fatigue in patients with solid tumours: A multicenter, observational and prospective study (PACS study). ESMO 2012
187. Gascon P. Intravenous iron : supplement or substitute to ESAs? ISOBM 2012 Congress, Jerusalem, Israel.
188. Gascón P, Casas A, de Castro J, Alberola V, Cucala M, Barón F. Anaemia-related fatigue in patients with solid tumours: a multicenter, observational and prospective study (PACS study), SEOM-Madrid 2012

## 23.- REVISIONS

1. Gascon P, Schwartz R: Kaposi's Sarcoma. Clinics of Dermatology 12:451- 456, 1994.
2. Gascon P. ¿Qué hay de nuevo en el uso de los factores de crecimiento? Revisiones en Cáncer 13:119-121, supl.2, 1999.
3. Gascon P, Schwartz R. Kaposi's sarcoma. New treatment modalities. Dermatology Clinics 18:169-175, 2000.

4. Martin M, Gascon P. Eritropoyetina: Optimización de los resultados de la radioterapia y la quimioterapia. Revisiones en Cáncer, 2000.
5. Nadal C, Gascon P. Inhibidores de la angiogénesis. Revisiones en Cáncer 16:22-25, 2002
6. Steen C, Gascon P., Schwartz RA. Factor II ([www.emedicine.com](http://www.emedicine.com)), 2004
7. Steen C, Gascon P., Schwartz RA. Factor X ([www.emedicine.com](http://www.emedicine.com)), 2004
8. Gallego R, Carcereny E, Gascon P. Darbepoetin alfa. Prous International, 2005
9. Gascón P. Nonisotopic detection of microRNA using digoxigenin labeled RNA probes. Mol Cell Probes 20: 1-4, 2006
10. Gascón P. Editor. Translational Oncology Reviews, Barcelona, 2007
11. Carcereny E, Gallardo E, Gascón P. Current approach in the use of erythropoietin. Cancer and Chemotherapy 2: 121-132, 2007
12. Gascón P. Epidemiología del Cáncer. Calidad de Vida en Oncología. Abril-Junio, núm 1, 2007
13. Gascón P. Optimización del tratamiento con EPO. Novedades Terapéuticas 4: 44-46, 2007
14. Gascón P. La stem cell cancerosa. Translational Oncology Reviews 2: 18-27, 2007
15. Jacot W, Gascón P., Jorgensen C. Développment des biothérapies en cancérologie. Dossier Biothérapie 13 (núm 5): 1-6, 2007
16. García-Albéniz X, Martínez-Fernández A, Gascón P. Combining targeted therapies. Targ Oncol 2: 241-252, 2007
17. Almendro V, Gascón P. Angiogenesis and the tumour microenvironment. Advances in Gastrointestinal Cancers 6: 3-6, 2008
18. Carcereny E, Viñolas N, Gascón P. Angiogenesis inhibitors in the treatment of non small-cell lung cancer (NSCLC). Clin Transl Oncol 10: 198-203, 2008
19. Gascón P. Revisión sobre la seguridad en el uso de agentes eritropoyéticos en tratamiento de la anemia. Anemia 2 (4): 149-154, 2009
20. Gascón P. Presently available biosimilars in hematology-oncology. Part II: G-CSF. Targeted Oncology, 2011 (in press)
21. Gascón P. Biosimilaires actuellement disponibles en hémato-oncologie- Partie II: G-CSF. Oncologie, 2011 (in press)
22. Gascón P. Biosimilares: epoetinas. BioPharmaceuticals 1(3): 15-23, 2012

1. Young N, Zoumbos N, Gascón P, Platanias L, Raefsky E: The immunologic pathophysiology of aplastic anemia: Implications for a viral etiology. In New Trends in Experimental Hematology. Oncogenes, Stem Cells, Bone Marrow Transplantation. Edited by Peschle, C. and Rizzoli c. pg. 117-126. Rome, 1984.
2. Bielory L, Gascón P: Immunohematology. In Allergy M.H. Lessof, T.H. Lee, D.M. Kemeny, editors. John Wiley and Sons, Publisher. chichester, England. pg 577-598, 1987.
3. Gascón P: "Aplasia modular adquirida: etiopatogenia y clinica" In Encyclopedia Hematologica Iberoamericana (EHIA). Edited by Lopez Borrasca, A. Salamanca, Spain, 1992.
4. Rameshwar P, Gascón P. Neural regulation of hematopoiesis by the tachykinins, Implication for a "fine tuned" hematopoietic regulation. Molecular Biology of Hematopoiesis (N.G. Abraham, S. Asano, G. Brittinger, and R Shadduck, eds). Plenum Press NY p.463-470, 1996.
5. Gascón P: Anemias. In Internal Medicine Textbook. J. Rodes and F. Guardia editors. Publisher Masson-Salvat, Vol I Chapter 54, Barcelona, Spain, 1996.
6. Gascón P, Schwartz R. Kaposi's sarcoma. New treatment modalities. Dermatology Clinics 18:169-175, 2000.
7. Gascón P: Tratamiento de soporte y cuidados paliativos en el enfermo con cáncer. In Internal Medicine textbook, Farreras-Rozman, Barcelona, Spain, 2000. ISBN: 978-84-8086-349-0
8. Nadal C, Gascón P. Bisfosfonatos en tumores con afectación ósea. In Bisfosfonatos en las enfermedades del metabolismo óseo y mineral. A. Rapado, M. Díez-Curiel editors, FHOEMO, Chapter 5, Madrid, Spain pp. 49-61, 2002.
9. Nadal C, Gascón P. Fármacos citostáticos y angiogénesis. Las nuevas dianas terapéuticas. In Angiogénesis tumoral y sus implicaciones en el tratamiento médico del cáncer. Diaz-Rubio, E., You & Us, Madrid,pg. 51-66, 2002
10. Gascón P: El cáncer, ¿se puede prevenir? ¿se puede curar?. En Manual de Salud para prevenir las enfermedades. Editorial Person Educación, Madrid, p.286-291, 2002. ISBN: 84-205-3595-8
11. Gascón P. Aplasia medular. Eritroblastopenias. In Hematología (Textbook). J. García-Conde, J.F. San Miguel, J. Sierra, V. Vicente, JL. Vives-Corrons, A. Urbano editors, Barcelona (in press)
12. Gascón P. Hemoglobinuria paroxística nocturna. In Hematología (Textbook). J. García-Conde, J.F. San Miguel, J. Sierra, V. Vicente, JL. Vives-Corrons, A. Urbano editors. Publisher Aran Ediciones S.A., Madrid, (in press)
13. Gascon P: Bladder Cancer. In Internal Medicine textbook, Farreras-Rozman, Barcelona, Spain,in press. ISBN: 978-84-8086-349-0
14. Gascon P, Rameshwar P. Transforming Growth Factor B 1 in Myelofibrosis, In Molecular Basis of Chronic Myeloproliferative Disorders. Petro E. Petrides and Heike L. Pahl editors. Springer-Verlag Berlin, 2004, pp.147-155. ISBN: 3-540-22485-8

15. Practical Guide in Solid Tumors (Guía Práctica de Tumores Sólidos). Esquemas de diagnóstico y tratamientos en neoplasias sólidas. A. Abad, Gascón P, E. Díaz-Rubio editors, Team Project, Madrid, 2004. ISBN: 978-84-692-3813-4
16. Gascon P: Anemias. In Internal Medicine Textbook. J. Rodés and F. Guardia editors. 2nd edition. Publisher Masson-Salvat, Vol I section H: Alteraciones Hematológicas pg.380-385, Barcelona, Spain, 2004. ISBN: 84-458-1319-6
17. González Barón M, Camps Herrero C, Gascon P et al. Anemia y Cáncer. Editorial Médica Panamericana S.A., 2005. ISBN: 84-7903-330-4
18. Lema L, Carcereny E, Gascon P. Controversias en el uso de los agonistas del receptor de la eritropoyetina. In Anemia en Cáncer. Monografías de Oncología. Editorial You and Us, Madrid, 2005
19. Gascon P. Anemia en Cáncer. Gascon P, Editor. Monografías de Oncología. Editorial You and Us, Madrid, 2005
20. López-Jiménez J, Gascón P, Odriozola J. Control de la emesis en el paciente oncohematológico. In Tratamiento de soporte en el paciente oncohematológico. Pg 29-50. Grupo Editorial Entheos S.L. Madrid, 2006. ISBN: 84-934269-7-0
21. Gallego R, Mármol M, Gascón P. Modificaciones post-traslacionales:inhibidores del proteasoma y de farnesil transferasa. In Monografías de Oncología Médica 2006. Nuevas dianas terapéuticas. Editorial You & Us, Madrid, pg.55-71, 2006
22. Practical Guide in Solid Tumors (Guía Práctica de Tumores Sólidos). Esquemas de diagnóstico y tratamientos en neoplasias sólidas. A. Abad, Gascon P, E. Díaz-Rubio editores, Team Project, Madrid, 2007.
23. Gascón P. Are there risks for iron use in cancer patients? In Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology - Scientific and Clinical Aspects of Anemia in Cancer. M.R. Nourousian editor. Springer-Verlag Wien, New York, 2007. ISBN: 978-3-211-25223-9
24. Garcia Y, Gascón P. Fármacos de apoyo (I): 155-172. Oncomecum. 2<sup>a</sup> Edición. 2007. Publicaciones Permanyer. ISBN: 978-84-92620-87-6
25. Gascón P. Co-Editor. Glosario del cáncer. Edita Asociación Española contra el cáncer, 2007. Depósito Legal: B-39.380-2007
26. Gascón P. ASCO Translational Oncology. Current Clinical Issues and Future Trends. Translacional oncology concepts pathways and targets. Clinical Oncology. Self-Study Series. (Vol I-II-III). Editors-in-chief: Platanias K an Gascón P. Medical Trends Barcelona, 2008. Depósito Legal: B-6.386-2008
27. Gascón P. ASCO Angiogenesis. Current Clinical Issues and Future Trends. Translacional oncology concepts pathways and targets. Clinical Oncology. Self-Study Series. (Vol I-II-III). Editors-in-chief: Lee M. Ellis, M.D and Gascón P. Medical Trends Barcelona, 2008. Depósito Legal: B.51.315-2008
28. Gascón P. ASCO Breast Cancer. Current Clinical Issues and Future Trends. Clinical Oncology. Self-Study Series (Vol I-II-III). Editors-in-chief: Perez Edith A and Gascón P, Medical Trends Barcelona, 2008. Depósito Legal: B-51.983-2007

29. Martínez A, García-Albéniz X, Gascón P. El receptor de eritropoyetina en el tratamiento de la anemia asociada al cáncer. In Radioterapia y anemia. Edición You and Us, Madrid, 2007; pp 57-70. ISBN: 978-84-690-4963-1
30. Nadal C, Almendro V, Gascón P. Metastatic signature in cancer cells: Breast cancer as model. In Cancer Metastasis, Editor: P. Rameshwar, Transworld Research Network, Kerala , India 2008: 1-15 ISBN: 978-81-7895-317-5
31. Muñoz M, Gascón P. El cáncer de mama. In Libro de la Salud del Hospital Clínic de Barcelona y la Fundació BBVA. Editor: Fundación BBVA. Bilbao, 2007. ISBN: 978-84-96515-33-8
32. Pineda E, Visa L, Gascón P. The appropriate use of molecular therapy. Pérez Manga, 2009.
33. Gallego R, Gallardo E, Gascón P. Toxicidad de la terapia antiangiogénica. Chapter 12 in Angiogénesis y Cáncer. Editors: Emilio Alba and Ana Rodríguez Quesada. TACTICS MD, S.L. 2009. ISBN 978-84-691-5241-6
34. Garcia Y, Gascón P. Fármacos de apoyo (I): 155-172. Oncomecum. 3<sup>a</sup> Edición. 2009. Publicaciones Permanyer. ISBN: 978-84-92620-87-6
35. Gascón P. ASCO Renal Cancer. Current Clinical Issues and Future Trends. Clinical Oncology. Self-Study Series (Vol I-II-III). Editors-in-chief: Eisen T and Gascón P, Medical Trends Barcelona, 2009. Depósito Legal: B-44.562-2008
36. Practical Guide in Solid Tumors (Guía Práctica de Tumores Sólidos). Esquemas de diagnóstico y tratamientos en neoplasias sólidas. A. Abad, Gascón P., E. Díaz-Rubio editores, Team Project, Madrid, 2009
37. Mármol M, Gascón P. Criterios de valoración en Oncología. En Oncología Radioterápica. Editor: Biete A y Calvo F. Ediciones Aran, SL, Madrid, 2009
38. Almendro V, Gascón P. Médula Ósea: Eritropoyetas. En Biología Molecular, Editor Foncillas J. Prous Science, S.A.U., Barcelona; pp 269-282, 2009. 978-84-8124-265-2
39. Gascón P. Síndromes linfoproliferativos crónicos. In Tratado de Oncología. Publicaciones Permanyer, Barcelona 2009. Pg 675-712. ISBN: 978-84-92620-18-0
40. Mármol M, Gascón P. Criterios de respuesta al tratamiento, en Oncología Radioterápica. Principios, métodos, gestión y práctica clínica. Aran Ediciones, pp 122-127, Madrid 2010. ISBN: 978-84-92977-05-5
41. Gascón P. Factores de colonias y hemoderivados. En Oncología Clínica. Volumen 1, pp 737-762. Editor M. González Barón. Madrid 2010. ISBN: 978-84-937307-3-4
42. Gascón P. Marcadores moleculares y nuevas terapias en cáncer de páncreas. En Avances en cáncer de páncreas, del laboratorio a la clínica. Edita: AECC y UCLM. Páginas 171-175. Albacete 2010. ISBN 978-84-693-9873-9
43. Gascón P. Biología molecular y perspectivas de futuro en los tratamientos en ginecología oncológica. En Cursos CLINIC de Formación Continuada en Obstetricia y Ginecología. Ed. Grupo Menarini, 2011. ISBN 978-84-8473-927-2

44. Almendro V, García-Recio S, Ametller E, Gascón P. Papel de las células madre tumorales en el desarrollo de metástasis. Monografías sobre el cáncer de mama metastásico, biblioteca Merk-Serono. Capítulo 7: 169-186, 2010. ISBN: 978-84-693-2431-8
45. Gascón P. ASCO Breast Cancer. Current Clinical Issues and Future Trends. Online Study Program. Editors-in-chief: Gascón P and Hurvitz S. Medical Trends Barcelona, 2011. <http://www.es-oncologycme.org/breastcancer>
46. Gaba L, Ortega V, Gascón P. Fármacos de apoyo (I): 189-211. In Oncomecum 2011 4<sup>a</sup> Edición. Publicaciones Permanyer, Barcelona. Pág. 189-212. ISBN: 978-84-9926-293-2
47. Nadal C, Gaba L, Gascón P. Anemia y Hematopoyesis. In Paciente Oncológico y Anemia. Editor Prof. Díaz- Rubio. Editorial You and Us. Madrid. Pág. 7-18. ISBN: 978-84-694-8513-2
48. Gascón P (editor), Garrido P (coordinator). ESMO Clinical Collection. Focus on Lung Cancer. Vol. I-II-III. Barcelona 2011. Depósito Legal: B.12.812.2011
49. Gascón.P /editor) Cuidados Continuos. You & Us (publisher), Madrid 2013
50. Visa L, Gascon P. Hedgehog as a new paradigm in cancer treatment in Stem Cells in Cancer: Should we believe it or not? JLA Aparicio & E Grande (editors), Springer SEM, NL, 2013 (en prensa)
51. Gascón P. Relevancia del ADCC en la respuesta a anticuerpos anti-EGFR. Oncology plus online. Editor: Prof. Jesús Garcia-Foncillas, 2013. [www.oncologyplusonline.com](http://www.oncologyplusonline.com) (en prensa)

## 25.- ALTRES PUBLICACIONS

---

1. Gascon P . Medical Correspondence in the USA (New York) JANO from 1976- 2003
2. Gascon P: The Acquired Immunodeficiency Syndrome. Guest editor JANO 729, 1986.
3. Gascon P, Bielory L: The immune system in the Acquired Immunodeficiency Syndrome. JANO 729:24-29, 1986.
4. Gascon P, Bielory L: Patología clínica del SIDA. JANO 729:31-44, 1986.
5. Schwartz RA, Gascon P: Síndrome de Torre (Muir-Torre): una consideración sobre un caso de carcinomas sebáceos múltiples. Med cutánea Ibero-Lat. Am. 22:40, 1994.
6. Gascon P: Aspectos biológicos del trasplante de médula ósea. Fundación BBV. Centenario de la Academia de Ciencias Médicas de Bilbao, 1995
7. Schwartz RA, Centurion SA, Gascon P. Avitaminosis A. eMedicine from WebMD. Updated December 11, 2009. Available at: <http://emedicine.medscape.com/article/1104441-overview>.
8. Gascon P. eMedicine article Vitamin A Deficiency in Dermatology, 2009, 2012 (<http://emedicine.medscape.com/article/1104441-overview>).

9. Schwartz RA, Steen CJ, Gascon P. Factor II. eMedicine from WebMD. Updated February 02, 2011. Available at: <http://emedicine.medscape.com/article/209742-overview>.
10. Schwartz RA, Steen CJ, Gascon P. Factor X. eMedicine from WebMD. Updated February 02, 2011. Available at: <http://emedicine.medscape.com/article/209867-overview>.
11. Schwartz RA, Kluijsszo E, Gascon P, McKenna R. Factor XIII. eMedicine from WebMD. Updated March 25, 2011. Available at: <http://emedicine.medscape.com/article/209179-overview>